EXHIBIT 10.90

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

2015 SUPPLY AGREEMENT
This 2015 SUPPLY AGREEMENT is made and entered into on this 10th day of
February, 2015 (the “Agreement Date”) and shall be effective as of February 10,
2015 (the “Effective Date”), by and among MICRON TECHNOLOGY, INC., a Delaware
corporation (“Micron”), MICRON SEMICONDUCTOR ASIA PTE. LTD., a Singapore private
limited company and wholly-owned Subsidiary (as defined hereinafter) of Micron
(the “Purchaser”), and INOTERA MEMORIES, INC. (Inotera Memories, Inc.
[Translation from Chinese]), a company incorporated under the laws of the
Republic of China (the “R.O.C.”) (“Inotera”).
RECITALS
A.    Inotera is engaged in the manufacture of DRAM Products (as defined
hereinafter) in wafer form.
B.    Micron, the Purchaser and Inotera (each, a “Party” and collectively, the
“Parties”) desire Inotera to generally supply Conforming Wafers (as defined
hereinafter), Pre-Qual Engineering Wafers (as defined hereinafter), Pre-Qual
Production Wafers (as defined hereinafter) and Non-Conforming Wafers (as defined
hereinafter) to the Purchaser upon the terms and subject to the conditions set
forth in this Agreement.
C.    The Parties desire to amend and restate the First Amended and Restated
Supply Agreement, dated December 19, 2013 and effective as of January 1, 2014,
by and among the Parties (the “Existing Supply Agreement”), in order to, among
other things, provide that the Term (as defined hereinafter) will expire on
December 31, 2015.
D.    On the Agreement Date, the Parties are also entering into a 2016 Supply
Agreement (the “2016 Supply Agreement”) providing for (i) a two (2)-year term
commencing as of January 1, 2016 and continuing until, but not including,
January 1, 2018, subject to extension as provided therein, and (ii) a three
(3)-year wind-down period commencing immediately following such term.
E.    It is the present intention of the Parties that the level of mutual
cooperation and support among the Parties in connection with their performance
of this Agreement be consistent with the level of mutual cooperation and support
among the Parties in connection with their performance of the Existing Supply
Agreement.
AGREEMENT
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties intending to be legally bound do
hereby agree as follows:

1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ARTICLE 1
DEFINITIONS; CERTAIN INTERPRETIVE MATTERS
1.1    Definitions. In addition to the terms defined elsewhere in this
Agreement, capitalized terms used in this Agreement shall have the respective
meanings set forth below:
“Affiliate” means, with respect to any specified Person, any other Person that
directly or indirectly, including through one or more intermediaries, Controls,
or is Controlled by, or is under common Control with such specified Person; and
the term “affiliated” has a meaning correlative to the foregoing.
“Agreement” means this 2015 Supply Agreement, together with the Schedules
attached hereto (but excluding the sample calculations set forth in any
attachments to such Schedules, which are provided for illustrative purposes only
and shall not constitute terms hereof).
“Agreement Date” shall have the meaning set forth in the preamble to this
Agreement.
“[***]” means, for any particular Design ID in a particular Delivery Month, if
the [***] are to be included in the Final Price of Non-HMC Conforming Wafers,
Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC Pre-Qual
Production Wafers delivered to the Purchaser in such Delivery Month in
accordance with Section 3.7, the product of (i) the [***] for such Delivery
Month, multiplied by (ii) the quotient of (A) the number of Non-HMC Conforming
Wafers, Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC
Pre-Qual Production Wafers of such Design ID delivered to the Purchaser in such
Delivery Month, divided by (B) the number of Non-HMC Conforming Wafers, Non-HMC
Pre-Qual Production Wafers, HMC Conforming Wafers and HMC Pre-Qual Production
Wafers of all Design IDs delivered to the Purchaser in such Delivery Month.
“[***]” means, for any particular Design ID in a particular Delivery Month, if
Inotera is required to include [***] in the Final Price of Non-HMC Conforming
Wafers, Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC
Pre-Qual Production Wafers delivered to the Purchaser in such Delivery Month
pursuant to Section 3.8(d), the product of (i) the [***] for all [***] required
to be included in the Final Price of Non-HMC Conforming Wafers, Non-HMC Pre-Qual
Production Wafers, HMC Conforming Wafers and HMC Pre-Qual Production Wafers
delivered to the Purchaser in such Delivery Month pursuant to Section 3.8(d),
multiplied by (ii) the quotient of (A) the number of Non-HMC Conforming Wafers,
Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC Pre-Qual
Production Wafers of such Design ID delivered to the Purchaser in such Delivery
Month, divided by (B) the number of Non-HMC Conforming Wafers, Non-HMC Pre-Qual
Production Wafers, HMC Conforming Wafers and HMC Pre-Qual Production Wafers of
all Design IDs delivered to the Purchaser in such Delivery Month.
“[***]” means, for any particular Design ID in a particular Delivery Month, if
the [***] for a particular [***] is to be included in the Final Price of Non-HMC
Conforming Wafers, Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and
HMC Pre-Qual Production Wafers

2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

delivered to the Purchaser in such Delivery Month in accordance with
Section 3.8(b), the product of (i) the [***] for all [***] for such Delivery
Month, multiplied by (ii) the quotient of (A) the number of Non-HMC Conforming
Wafers, Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC
Pre-Qual Production Wafers of such Design ID delivered to the Purchaser in such
Delivery Month, divided by (B) the number of Non-HMC Conforming Wafers, Non-HMC
Pre-Qual Production Wafers, HMC Conforming Wafers and HMC Pre-Qual Production
Wafers of all Design IDs delivered to the Purchaser in such Delivery Month.
“Annual Calendar” shall have the meaning set forth in Section 3.2.
“Applicable Law” means any applicable laws, statutes, rules, regulations,
ordinances, orders, codes, arbitration awards, judgments, decrees or other legal
requirements of any Governmental Entity.
“Applicable [***] Deadline” means the later to occur of (a) the date that is
[***] months after [***] in the Micron Fab Network and (b) the date that is
[***] months after [***] on the agreed upon representative toolset created using
a [***] at the Inotera Fab, as [***], where necessary and appropriate, with
[***] at other fabs in the Micron Fab Network; provided, however, that, if such
[***] at another fab in the Micron Fab Network has not [***] by the end of the
[***] month of such [***]-month period, such period shall be suspended until
such [***] at another fab in the Micron Fab Network has [***].
“Applicable [***] Target” means:
(a)     if the [***] sufficient and appropriate for [***] on the [***], as
forecasted in good faith by Micron, is less than [***], [***];
(b)     if the [***] sufficient and appropriate for [***] on the [***], as
forecasted in good faith by Micron, is (i) equal to or greater than [***] and
(ii) less than [***], [***];
(c)     if the [***] sufficient and appropriate for [***] Wafer Starts per week
on the [***], as forecasted in good faith by Micron, is (i) equal to or greater
than [***] and (ii) less than [***], [***];
(d)     if the [***] sufficient and appropriate for [***] on the [***], as
forecasted in good faith by Micron, is (i) equal to or greater than [***] and
(ii) less than [***], [***]; and
(e)     if [***] sufficient and appropriate for [***] on the [***], as
forecasted in good faith by Micron, is (i) equal to or greater than [***] and
(ii) less than [***], [***].
“Boundary Conditions” means, with respect to the Inotera Fab, a requirement
that, at any point in time:

DLI-266520155v1
3

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(a)    there shall be [***] in use for the manufacture of DRAM Products,
provided that at the Inotera Fab, there also may be [***] in use for [***];
(b)    subject to clause (c) below, the Inotera Fab shall manufacture for the
Purchaser DRAM Products with [***]; provided, however, that if at any time the
Inotera Fab is manufacturing for the Purchaser DRAM Products with [***] (or, if
and when the [***] at the Inotera Fab, such [***] as is agreed in writing by the
Parties) and the Purchaser requests that the Inotera Fab manufacture for the
Purchaser DRAM Products with [***] by the Inotera Fab, the Inotera Fab shall
also manufacture for the Purchaser DRAM Products with [***] manufactured by the
Inotera Fab [***] to manufacture DRAM Products with [***], including such new
Design ID, would be [***] the following for [***] in the [***] the Inotera Fab
[***] being manufactured by or for Micron and its Affiliates at such fab [***],
for the Inotera Fab, [***] being manufactured at [***] at the Inotera Fab, [***]
DRAM Products (in wafer form) meeting the applicable specifications that can be
manufactured by or for Micron and its Affiliates at [***]; provided further,
however, that the foregoing shall be applied only to determine whether the
Inotera Fab [***] manufacture DRAM Products with [***] manufactured by the
Inotera Fab and only in the circumstance specified above and that the foregoing
shall not be applied on [***] or otherwise [***] in any circumstance [***] the
Purchaser to [***] the Inotera Fab to manufacture for the Purchaser DRAM
Products with [***] manufactured by the Inotera Fab;
(c)    the Inotera Fab shall not manufacture DRAM Products [***] for the
Purchaser unless, [***], the sum of (i) the [***] to be delivered in such [***]
plus (ii) the [***] delivered during such [***], is [***]; and
(d)     the Inotera Fab shall not manufacture DRAM Products [***] for the
Purchaser unless (i) the Inotera Fab [***] for such [***], or (ii) the Purchaser
has [***] for such DRAM Products [***] and such DRAM Products have been [***];
as such requirement may be altered from time to time by the Purchaser with the
consent of Inotera, which shall not be unreasonably withheld, conditioned or
delayed; provided, however, that, notwithstanding anything above to the
contrary, DRAM Products that are manufactured [***] shall be deemed to be DRAM
Products of a [***] for purposes of the [***] described in clauses (b) and (c)
above.
“Business Day” means a day that is not a Saturday, Sunday or other day on which
commercial banking institutions in either the R.O.C. or the State of New York
are authorized or required by Applicable Law to be closed.
“Business Plan” means, at any particular time, the three (3) year business plan
then existing for Inotera, as approved by the board of directors of Inotera.
“Closing Date” shall mean January 17, 2013.

DLI-266520155v1
4

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Committed Purchaser Manufacturing Capacity” means, at any time during the Term,
100% of the Manufacturing Capacity for each Process Node installed at the
Inotera Fab.
“Conforming Wafer” means a wafer containing DRAM Products produced by Inotera
for delivery to the Purchaser under this Agreement following the qualification
of such DRAM Products that (a) meets the applicable Specifications for a
Conforming Wafer containing such DRAM Products immediately after Probe Testing
and (b) has a minimum Die Yield equal to [***]% (or, if the minimum die yield
required for conforming wafers containing such DRAM Products in other fabs in
the Micron Fab Network is different than [***]%, then such different percentage,
which shall be set forth in a written notice to Inotera from Micron or the
Purchaser).
“Control” means the power or authority, whether exercised or not, to direct the
business, management and policies of a Person, directly or indirectly, whether
through the ownership of voting securities, by contract or otherwise, which
power or authority shall conclusively be presumed to exist upon possession of
beneficial ownership or power to direct the vote of more than fifty percent
(50%) of the votes entitled to be cast at a meeting of the members, shareholders
or other equity holders of such Person or power to control the composition of a
majority of the board of directors or like governing body of such Person; and
the term “Controlled” has a meaning correlative to the foregoing.
“Cycle-Time” means the time required to process a wafer through a portion of the
manufacturing process or through the manufacturing process as a whole, including
Probe Testing.
“Delivery Month” means, with respect to any particular wafer delivered to the
Purchaser pursuant to this Agreement, the Fiscal Month in which it is delivered
to the Purchaser.
“Demand Forecast” shall have the meaning set forth in Section 3.4.
“Design ID” means a part number that is assigned to a unique DRAM Design of a
particular DRAM Product, which may include a number or letter designating a
specific device revision.
“Die Yield” means the quotient, expressed as a percentage, of (a) the number of
DRAM Products in die form that are manufactured on a wafer and that meet the
applicable Specifications for such DRAM Products immediately after Probe
Testing, divided by (b) the maximum number of such die that could be
manufactured on such wafer to meet the applicable Specifications for such wafer
using the applicable Process Node.
“DRAM” means a dynamic random access memory cell that functions by using a
capacitor arrayed predominantly above the semiconductor substrate.
“DRAM Design” means all of the design elements, components, specifications and
information required to manufacture the subject DRAM Product.

DLI-266520155v1
5

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“DRAM Product” means any memory comprising DRAM, whether in die or wafer form.
“Effective Date” shall have the meaning set forth in the preamble to this
Agreement.
“Environmental Laws” means any and all laws, statutes, rules, regulations,
ordinances, orders, codes or binding determinations of any Governmental Entity
pertaining to the environment in any and all jurisdictions in which the Inotera
Fab is located, including laws pertaining to the handling of wastes or the use,
maintenance and closure of pits and impoundments, and other environmental
conservation or protection laws.
“Excursion” means a performance deviation during the production process that is
outside normal behavior, as defined by historical performance or as established
by the Purchaser and Inotera in writing in the applicable Specifications, which
may impact performance, Quality and Reliability or the Purchaser’s customer
delivery commitments for DRAM Product from Conforming Wafers.
“Existing Supply Agreement” shall have the meaning set forth in Recital C to
this Agreement.
“Final Invoice” shall have the meaning set forth in Section 4.9(b).
“Final Price” shall have the meaning set forth in Section 5.2.
“Fiscal Month” means any of the twelve financial accounting months within the
Fiscal Year.
“Fiscal Quarter” means any of the four financial accounting quarters within the
Fiscal Year.
“Fiscal Year” means the fiscal year of Inotera for financial accounting
purposes.
“[***]” shall have the meaning set forth in Schedule 3.7.
“[***]” shall have the meaning set forth in Section 3.7.
“Force Majeure Event” means the occurrence of an event or circumstance beyond
the reasonable control of the Party and includes: (a) explosions, fires, flood,
earthquakes, catastrophic weather conditions, or other elements of nature or
acts of God; (b) acts of war (declared or undeclared), acts of terrorism,
insurrection, riots, civil disorders, rebellion or sabotage; (c) acts of
Governmental Entities; (d) labor disputes, lockouts, strikes or other industrial
action, whether direct or indirect and whether lawful or unlawful; (e) failures
or fluctuations in electrical power or telecommunications service or equipment;
and (f) delays caused by nonperformance of Inotera, in the case of Micron or the
Purchaser, or Micron or the Purchaser, in the case of Inotera, or nonperformance
by a Third Party (except for delays caused by such Party’s subcontractors or
agents).

DLI-266520155v1
6

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“GAAP” means generally accepted accounting principles.
“Governmental Entity” means any governmental authority or entity, including any
agency, board, bureau, commission, court, municipality, department, subdivision
or instrumentality thereof, or any arbitrator or arbitration panel.
“Hazardous Substances” means any asbestos, any flammable, explosive,
radioactive, hazardous, toxic, contaminating, polluting matter, waste or
substance, including any material defined or designated as a hazardous or toxic
waste, material or substance, or other similar term, under any Environmental
Laws in effect or that may be promulgated in the future.
“HMC Conforming Wafer” means Conforming Wafers for HMC DRAM Products.
“HMC DRAM” means a hybrid memory cube dynamic random access memory cell that is
intended to be coupled with a controller or logic chip.
“HMC DRAM Product” means any memory comprising HMC DRAM, whether in die or wafer
form.
“HMC Pre-Qual Engineering Wafers” means Pre-Qual Engineering Wafers for HMC DRAM
Products.
“HMC Pre-Qual Production Wafers” means Pre-Qual Production Wafers for HMC DRAM
Products.
“HMC Wafer” means a wafer containing HMC DRAM Products.
“Indemnified Losses” mean all direct, out-of-pocket liabilities, damages,
losses, costs and expenses (including reasonable attorneys’ and consultants’
fees and expenses).
“Indemnified Party” shall have the meaning set forth in Section 9.2(a).
“Indemnifying Party” shall have the meaning set forth in Section 9.2(a).
“Inotera” shall have the meaning set forth in the preamble to this Agreement.
“Inotera Fab” shall have the meaning set forth in Section 1.2(c).
“Inotera Financial Report” shall have the meaning set forth in Section 3.11.
“[***]” has the meaning set forth on Schedule 3.8.
“[***]” has the meaning set forth in Section 3.8(e).

DLI-266520155v1
7

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Joint Venture Agreement” means that certain Joint Venture Agreement between
MNL, Numonyx B.V., MTAP and NTC, dated as of the Closing Date, as amended,
relating to Inotera.
“Line Yield” means, for any given period of time, the quotient, expressed as a
percentage, of (a) the number of Conforming Wafers, Pre-Qual Engineering Wafers
and Pre-Qual Production Wafers produced during such period of time, divided by
(b) the number of all wafers started during such period of time.
“Long Range Forecast” shall have the meaning set forth in Section 3.15.
“Manufacturing Capacity” means, for each Process Node at the Inotera Fab for any
particular period of time, the maximum number of Conforming Wafers that can be
manufactured through Probe Testing and delivered to the Purchaser utilizing such
Process Node at the Inotera Fab during such period of time, assuming Inotera
only manufactured Conforming Wafers during such period of time.
“Manufacturing Plan” shall have the meaning set forth in Section 3.1.
“Mask [***]” has the meaning set forth in Section 2.3(b).
“Micron” shall have the meaning set forth in the preamble to this Agreement.
“Micron Fab Network” means the fabs manufacturing DRAM Products for Micron and
its Affiliates, including the Inotera Fab.
“Micron/Inotera Confidentiality Agreement” means that certain Mutual
Nondisclosure Agreement between Micron and Inotera, dated as of the Closing
Date, as amended.
“[***]” shall have the meaning set forth in Section 3.12(e).
“MNL” means Micron Semiconductor B.V., a private limited liability company
organized under the laws of the Netherlands.
“Monthly Planning Statement” shall have the meaning set forth in Section 3.3.
“Monthly Financial Review” shall have the meaning set forth in Section 3.14(b).
“MTAP” means Micron Technology Asia Pacific, Inc., an Idaho corporation.
“Non-Conforming Wafer” means a wafer containing DRAM Products produced by
Inotera for delivery to the Purchaser under this Agreement following the
qualification of such DRAM Products that (a) fails to meet the applicable
Specifications for a Conforming Wafer containing such DRAM Products immediately
after Probe Testing or (b) has a minimum Die Yield below that required for a
Conforming Wafer of such DRAM Products.

DLI-266520155v1
8

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Non-HMC Conforming Wafer” means Conforming Wafers for Non-HMC DRAM Products.
“Non-HMC DRAM Product” means any memory comprising DRAM and excluding HMC DRAM,
whether in die or wafer form.
“Non-HMC Pre-Qual Engineering Wafers” means Pre-Qual Engineering Wafers for
Non-HMC DRAM Products.
“Non-HMC Pre-Qual Production Wafer” means Pre-Qual Production Wafers for Non-HMC
DRAM Products.
“NTC” means Nanya Technology Corporation (Nanya Technology Corporation
[Translation from Chinese]), a company incorporated under the laws of the R.O.C.
“Numonyx B.V.” means Numonyx Holdings B.V., a private limited liability company
organized under the laws of the Netherlands.
“Operational Report” shall have the meaning set forth in Section 3.12.
“[***]” shall have the meaning set forth in Section 11.2(c).
“Party” and “Parties” shall have the meanings set forth in Recital B to this
Agreement.
“Performance Criteria” means the factors of [***].
“Permitted Disclosures” shall have the meaning set forth in Section 3.16.
“Person” means any natural person, corporation, joint stock company, limited
liability company, association, partnership, firm, joint venture, organization,
business, trust, estate or any other entity or organization of any kind or
character.
“Preliminary Price” means, for a particular Delivery Month, (a) with respect to
Non-HMC Conforming Wafers and Non-HMC Pre-Qual Production Wafers, Inotera’s
estimate, as of the time Inotera delivers the Preliminary Price Notice with
respect to such Delivery Month, of the Price that Inotera will charge pursuant
to Schedule 5.1 of this Agreement for such Non-HMC Conforming Wafers and Non-HMC
Pre-Qual Production Wafers, as reasonably determined by Inotera, with such
estimate being based on the [***], for the [***], for products [***] to such
[***] (or such other [***], or combination or derivation therefrom, as the
Parties may mutually agree in writing), (b) with respect to HMC Conforming
Wafers and HMC Pre-Qual Production Wafers, [***] to be negotiated in good faith
by the Parties pursuant to Section 5.1(c) and 5.1(d) prior to Inotera loading
any HMC Wafers; (c) with respect to Pre-Qual Engineering Wafers, [***], and (d)
with respect to Non-Conforming Wafers, an amount [***] per Non-Conforming Wafer,
as mutually agreed in writing by the Parties.

DLI-266520155v1
9

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Preliminary Price Notices” shall have the meaning set forth in Section 4.4(a).
“Pre-Qual Engineering Wafers” means, with respect to a particular DRAM Product,
wafers of such DRAM Product requested by the Purchaser for delivery to the
Purchaser in lieu of Conforming Wafers in any Purchase Order placed, or any
change order to a Purchase Order issued, as contemplated by Section 4.3, that
are manufactured to the full extent of the applicable process flow but prior to
the qualification of such DRAM Product at the Inotera Fab; provided, however,
that in no event shall the following be deemed Pre-Qual Engineering Wafers: (i)
engineering wafers for the first iteration (excluding subsequent device
revisions) with an intention to qualify of the first Design ID on any particular
Process Node, which engineering wafers will not be manufactured under this
Agreement but instead will be subject to a separate statement of work providing
for cost sharing pricing, which statement of work and the specific cost sharing
percentage shall be negotiated in good faith by the Parties prior to
manufacturing of such engineering wafers; and (ii) Pre-Qual Production Wafers.
“Pre-Qual Production Wafers” means, with respect to a particular DRAM Product
having a qualification plan, prior to the qualification of such DRAM Product at
the Inotera Fab, the wafers delivered by Inotera in excess of the first two
hundred (200) wafers on a particular Design ID that were deemed Pre-Qual
Engineering Wafers provided that at least one fab in the Micron Fab Network has
achieved 50% Probe Yield as of the beginning of the respective Delivery Month.
“Price” shall have the meaning set forth in Section 5.1.
“Price True-Up Amount” means, for a particular Delivery Month, an amount, which
may be positive or negative, equal to the sum of (i) the sum of (A) the
aggregate Final Price of the Non-HMC Conforming Wafers, Non-HMC Pre-Qual
Production Wafers, HMC Conforming Wafers, and HMC Pre-Qual Production Wafers
delivered during such Delivery Month to the Purchaser calculated in accordance
with Section 5.2, plus (B) the aggregate price of Pre-Qual Engineering Wafers
delivered during such Delivery Month to the Purchaser pursuant to Section 5.3,
minus (ii) the aggregate balance owing to Inotera shown on all Pro Forma
Invoices accompanying the deliveries of Non-HMC Conforming Wafers, Non-HMC
Pre-Qual Production Wafers, HMC Conforming Wafers, HMC Pre-Qual Production
Wafers, Pre-Qual Engineering Wafers, and Non-Conforming Wafers during such
Delivery Month to the Purchaser.
“Probe Testing” means testing, using a wafer test program as set forth in the
applicable Specifications for such wafer, of a wafer that has completed all
processing steps deemed necessary to complete the creation of the desired
integrated circuits in the die on such wafer, the purpose of which test is to
determine how many and which of the die meet the applicable criteria for such
die set forth in the Specifications for such die.
“Probe Yield” means, with respect to any period of time, the quotient, expressed
as a percentage, of (a) the number of DRAM Products in die form meeting the
applicable Specifications for such DRAM Products during such period of time,
divided by (b) the maximum number of die on Conforming Wafers probed during such
period of time.

DLI-266520155v1
10

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Process Node” means a collection of process technology and equipment that
enables the production of DRAM Products in wafer form for a particular minimum
repeatable half pitch of a device (minimum physical feature size or line width)
and often designated by the size of such pitch (e.g., the 42nm Process Node or
the 30nm Process Node, etc.). For the avoidance of doubt, the Parties
acknowledge and agree that the [***] Process Node utilized at the Inotera Fab is
not the same Process Node as the [***] Process Node utilized by [***].
“Pro Forma Invoice” shall have the meaning set forth in Section 4.9(a).
“[***]” shall have the meaning set forth in Section 3.8(a).
“Purchase Order” shall have the meaning set forth in Section 4.4(b).
“Purchaser” shall have the meaning set forth in the preamble to this Agreement.
“Purchaser Indemnified Party” means the Purchaser or any of its Affiliates,
including Micron.
“[***]” shall have the meaning set forth in Section 3.9.
“Purchaser Pricing Report” shall have the meaning set forth in Section 3.13.
“[***]” shall have the meaning set forth in Section 3.8(b).
“Quality and Reliability” means the quality and reliability standards for
Conforming Wafers as set forth on Schedule 1.1 and in the applicable
Specifications for such Conforming Wafers or the Manufacturing Plan in effect
from time to time.
“Quarterly Business Review” has the meaning set forth on Section 3.14(a).
“Recoverable Taxes” shall have the meaning set forth in Section 4.8(a).
“[***] Notice” shall have the meaning set forth in Section 3.8(a).
“[***] Notice” shall have the meaning set forth in Section 3.8(b).
“Response to Forecast” shall have the meaning set forth in Section 3.5.
“Restriction Period” means, with respect to any Segregated Employee, the period
of time beginning on the date such Person becomes a Segregated Employee and
ending on the date that is [***] months after the date such Person is no longer
a Segregated Employee.

DLI-266520155v1
11

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“R.O.C.” shall have the meaning set forth in the preamble to this Agreement.
“[***] Payment Amount” shall have the meaning set forth in Section 3.13.
“Segregated Employees” means (a) the accounting employees of Inotera that are
responsible for performing, reviewing and approving the calculation of the Price
for any DRAM Product sold to the Purchaser under this Agreement, and (b) the
president of Inotera and the senior officer responsible for financial management
of Inotera, provided that no [***], if any, shall be permitted to be a
Segregated Employee.
“Shared Design ID Wafers” means all wafers with the same Design ID that are
produced for both the Purchaser and other Persons.
“Ship Lot Line Yield” means, with respect to any lot of wafers, the quotient,
expressed as a percentage, of (a) the number of Conforming Wafers manufactured
from such lot, divided by (b) the number of Wafer Starts from such lot.
“Specifications” means those specifications used to describe, characterize, and
define the quality and performance of a Conforming Wafer or a DRAM Product in
die form, as applicable, in each case, as such specifications may be set forth
on Schedule 1.1 or otherwise determined from time to time by the Purchaser and
delivered in writing to Inotera; provided, however, that (a) with respect to
specifications not in effect on the Effective Date, (i) promptly upon receipt by
Inotera from the Purchaser of such specifications, Inotera shall evaluate such
specifications and, without undue delay, the Purchaser and Inotera shall
mutually agree upon the effective date for such specifications (which date shall
in no event be more than [***] days following Inotera’s receipt of such
specifications from the Purchaser, unless a later date is agreed upon by the
Purchaser and Inotera) and (ii) upon reaching such agreement, Inotera shall
confirm to the Purchaser in writing the agreed effective date for such
specifications and (b) specifications delivered by the Purchaser to Inotera for
Conforming Wafers containing a particular DRAM Product or a DRAM Product in die
form shall [***] specifications for wafers containing such particular DRAM
Product or such DRAM Product in die form, as applicable (if any), [***].
“Subsidiary” means, with respect to any specified Person, any other Person that
directly or indirectly, including through one or more intermediaries, is
Controlled by such specified Person.
“Swap Ratio” means, with respect to any Pre-Qual Engineering Wafer, a ratio that
will be used to [***] of such Pre-Qual Engineering Wafer to take into account
the [***] required to produce such wafer compared to a Conforming Wafer
generally, as such ratio is agreed by the Parties from time to time; provided,
however, that, if the Parties cannot agree to such ratio for any particular
Pre-Qual Engineering Wafer, the ratio for such Pre-Qual Engineering Wafer will
be reasonably determined by the Purchaser.

DLI-266520155v1
12

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“Taiwan GAAP” means GAAP used in the R.O.C., as in effect from time to time,
consistently applied for all periods at issue.
“Term” shall have the meaning set forth in Section 11.1.
“Third Party” means any Person, other than Micron, Inotera or any of their
respective Subsidiaries.
“Third Party Claim” means any claim, demand, lawsuit, complaint, cross-complaint
or counter-complaint, arbitration, opposition, cancellation proceeding or other
legal or arbitral proceeding of any nature brought in any court, tribunal or
judicial forum anywhere in the world, regardless of the manner in which such
proceeding is captioned or styled brought by any Third Party.
“2016 Supply Agreement” shall have the meaning set forth in Recital D to this
Agreement.
“[***]” shall have the meaning set forth in Schedule 3.8.
“[***]” shall have the meaning set forth in Section 3.8(e).
“Wafer Start” means the initiation of manufacturing services with respect to a
wafer.
“WIP” means work in process at the Inotera Fab, including all wafers in wafer
fabrication and sort and all completed Conforming Wafers, Pre-Qual Engineering
Wafers, Pre-Qual Production Wafers, and Non-Conforming Wafers not yet delivered
to the Purchaser or other Persons.
“WIP Data” means in-line inventory data, including wafer numbers, lot numbers,
unit volumes, wafer volumes, Cycle-Times, Die Yield, Line Yield, Probe Yield and
Ship Lot Line Yield.
“WSTS Forecast” means the forecast of semiconductor prices prepared by WSTS,
Inc.
1.2    Certain Interpretive Matters.
(a)    Unless the context requires otherwise, (i) all references to Sections,
Articles, Exhibits, Appendices or Schedules are to Sections, Articles, Exhibits,
Appendices or Schedules of or to this Agreement, (ii) each accounting term not
otherwise defined in this Agreement (A) with respect to Micron or the Purchaser,
has the meaning commonly applied to it in accordance with GAAP used in the
United States, as in effect from time to time, consistently applied for all
periods at issue, and (B) with respect to Inotera, has the meaning commonly
applied to it in accordance with Taiwan GAAP, (iii) words in the singular
include the plural and vice versa, (iv) the term “including” means “including
without limitation,” and (v) the terms “herein,” “hereof,” “hereunder” and words
of similar import shall mean references to this Agreement as a whole and not to
any individual section or portion hereof. All references to “$” or dollar
amounts will be to lawful currency of the United States of America. All
references to “day” or “days” mean calendar

DLI-266520155v1
13

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

days, and all references to “quarter(ly),” “month(ly)” or “year(ly)” mean Fiscal
Quarter, Fiscal Month or Fiscal Year, respectively, unless the context requires
otherwise.
(b)    No provision of this Agreement will be interpreted in favor of, or
against, any Party by reason of the extent to which (i) such Party or its
counsel participated in the drafting thereof, or (ii) such provision is
inconsistent with any prior draft of this Agreement or such provision.
(c)    For purposes of this Agreement, the “Inotera Fab” shall mean collectively
the existing fabs of Inotera commonly referred to as “Fab 1,” “Fab 2” and “Fab
1A” located at Hwa Ya Technology Park, Taoyuan, Taiwan.
(d)    Notwithstanding anything herein to the contrary, the example calculations
set forth in any attachments to the Schedules hereto shall not constitute terms
of this Agreement and are provided for illustrative purposes only. In the event
of any conflict between such example calculations and the terms of this
Agreement, the terms of this Agreement shall govern and the Parties shall modify
such example calculations to be consistent therewith.
ARTICLE 2
OBLIGATIONS OF THE PARTIES;
PROCESSES AND CONTROLS
2.1    General Obligations.
(a)    Inotera shall provide, develop and operate the Inotera Fab according to
the Business Plan in effect from time to time and the obligations set forth
herein (including the planning process set forth in Article 3).
(b)    Inotera shall:
(i)    manufacture Conforming Wafers for the Purchaser in accordance with
(A) the applicable Boundary Conditions, (B) the applicable Specifications,
(C) the Responses to Forecast developed in response to the Demand Forecasts
provided by the Purchaser to Inotera in accordance with Article 3;
(ii)    supply Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, and Non-Conforming Wafers to the Purchaser in accordance with
the purchasing process set forth in Article 4; and

DLI-266520155v1
14

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(iii)    operate the Inotera Fab so that DRAM Product output from the Inotera
Fab does not differ materially from that of any other fab in the Micron Fab
Network as to the Specifications and Performance Criteria.
(c)    The Purchaser shall purchase Conforming Wafers, Pre-Qual Engineering
Wafers, Pre-Qual Production Wafers, and Non-Conforming Wafers from Inotera in
accordance with the terms and conditions set forth herein.
For the avoidance of doubt, in no event shall Inotera be obligated to load any
HMC Wafers unless and until the Parties have first negotiated and agreed as to
how to calculate the Price of HMC Conforming Wafers as contemplated by Section
5.1(c) and the Price of HMC Pre-Qual Wafers as contemplated by Section 5.1(d).
2.2    Control; Processes. The Purchaser and Inotera shall review Inotera’s
control and process mechanisms, including such mechanisms that are utilized to
ensure that all parameters of the Specifications and Performance Criteria are
met or exceeded in Inotera’s manufacture of Conforming Wafers. The Purchaser and
Inotera agree to work together in good faith to define mutually agreeable
control and process mechanisms, including the following: (a) e-test (also known
as parametric test capability); (b) qualification methodology plan; (c) product
qualification support; (d) Probe Testing capability; (e) change control process;
and (f) failure analysis capability and methodology. Without limiting the
generality of the foregoing, the Purchaser and Inotera agree to the control and
process mechanisms set forth in Schedule 1.1.
2.3    Production Masks.
(a)    Inotera shall purchase masks required to manufacture [***] for DRAM
Products manufactured by Inotera under this Agreement from [***], and Inotera
may purchase masks required to manufacture [***] for DRAM Products manufactured
by Inotera under this Agreement from [***] (other than [***] approved in writing
by Micron; provided, however, that, with respect to Inotera’s purchase of any
[***], such limitations shall not apply if [***]. Furthermore, [***] shall meet
[***] at [***] for [***]. If Inotera elects to purchase masks from [***],
subject to [***] (such [***] to be determined in [***] sole discretion), [***]
will provide to [***] the [***] determines, in its sole discretion, are
necessary to [***]. To the extent [***] provides [***] as contemplated by the
immediately preceding sentence, Inotera will pay to [***] associated with such
[***] promptly after receiving an invoice in connection therewith.
Notwithstanding anything in this Section 2.3(a) to the contrary, [***] shall be
used for the [***] and any [***] of each [***] for a DRAM Product of [***].
Inotera shall have possession, but not ownership of any underlying copyrights,
mask works or other intellectual property, of any physical production masks
which Inotera obtains in accordance with this Section 2.3(a).
(b)    Inotera shall promptly revise at Inotera’s expense any mask set that is
being utilized for the manufacture of DRAM Products by Inotera for delivery to
the Purchaser under this Agreement as requested by the Purchaser or Micron from
time to time; provided, however, that, if [***] to the initial mask set [***] as
so revised before such mask set is [***], the [***] such initial

DLI-266520155v1
15

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

mask set (the “Mask [***]”), excluding any [***] for any [***], will be [***] in
the [***] in the Delivery Month [***] in which [***].
2.4    Designation of WIP.
(a)    WIP Associated With Shared Design ID Wafers. Inotera shall ensure that
WIP at the Inotera Fab associated with Shared Design ID Wafers is designated for
the Purchaser and any other Persons for which it is produced from Wafer Start,
and the Shared Design ID Wafers shall be allocated to the Purchaser and such
other Persons immediately prior to Probe Testing by Design ID pro rata in
accordance with the relative number of Wafer Starts of such Shared Design ID
Wafers for each of the Purchaser and such other Persons during the Fiscal Month
in which such Shared Design ID Wafers were started.
(b)    Other WIP. Inotera shall ensure that WIP at the Inotera Fab associated
with wafers (other than the Shared Design ID Wafers contemplated by
Section 2.4(a)) to be produced for the Purchaser or any other Person is
designated for the Purchaser or such other Person, as applicable, from Wafer
Start.
2.5    Subcontractors. Inotera may utilize [***] as a subcontractor, subject to
(a) the prior written approval of the Purchaser, which approval shall not be
unreasonably withheld or delayed, and (b) compliance with the guidelines
developed to manage the quality of such utilization in effect on the Effective
Date (with such changes thereto as may from time to time be agreed in writing by
the Parties). Inotera shall ensure that all contracts with [***] (a) shall
provide Inotera with the same level of access and controls as Inotera provides
to the Purchaser in this Agreement and (b) contain customary nondisclosure
obligations in a form reasonably acceptable to the Purchaser.
2.6    [***] Notification. In addition to the Operational Report and the
Quarterly Business Review, Inotera shall promptly notify the Purchaser of [***]
affecting [***].
2.7    Traceability; Data Retention. The Purchaser and Inotera shall review
Inotera’s (a) [***] and producing the WIP Data and (b) data retention policy in
regards to the WIP Data. Inotera agrees to maintain the WIP Data for a minimum
of [***] (or such other period as may be agreed in writing by the Parties).
2.8    Access to WIP Data. Inotera shall provide the Purchaser with full access
to its WIP Data (including with respect to Shared Design ID Wafers) no less
frequently than [***] under normal circumstances, which data shall be no older
than [***] old when accessed.
2.9    Additional Customer Requirements. The Purchaser shall inform Inotera in
writing of any supplier requirements of any customer of the Purchaser relating
to the Inotera Fab. The Purchaser and Inotera shall work together in good faith
to satisfy such requirements.

DLI-266520155v1
16

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

2.10    [***]. Inotera will continue to cooperate with Micron and the Purchaser,
and work in good faith, to develop a [***] plan, including (a) agreeing in
writing to a [***] for the [***] at the Inotera Fab, which may be updated from
time to time by the Parties in writing; (b) [***] at the Inotera Fab that, as
[***], where necessary and appropriate, with [***] at other fabs in the Micron
Fab Network, constitutes the agreed upon [***] for the [***] at the Inotera Fab;
(c) through the [***] the Inotera Fab and other fabs in the Micron Fab Network
as necessary and appropriate, [***] on the agreed upon [***] using the [***]
described in clause (b), as [***], where necessary and appropriate, with [***]
at other fabs in the Micron Fab Network and thereafter [***] necessary to
complete the [***]; and (d) within [***] months after [***] on such [***] on
such [***] on such [***].
ARTICLE 3
PLANNING AND FORECASTING;
PERFORMANCE REVIEWS AND REPORTS
3.1    Annual Manufacturing Plan. At least [***] days (or such other number of
days as may be agreed in writing by the Parties) prior to the end of each Fiscal
Year, Inotera shall prepare, under the direction of the president of Inotera, an
annual manufacturing plan (the “Manufacturing Plan”) for the next [***] (or such
other period or periods as may be agreed in writing by the Parties) and shall
submit the Manufacturing Plan to the Purchaser for its review and comment. The
Manufacturing Plan shall reflect the planning process contained in this Article
3. The Manufacturing Plan shall address various manufacturing issues, including
the DRAM Products to be manufactured, a loading plan (by Design ID and Process
Node for the DRAM Products to be produced, including, if applicable, a breakout
of the DRAM Products, by Design ID and Process Node, to be produced for any
Persons other than the Purchaser) and weekly loading and output (including, if
applicable, a breakout, by Design ID and Process Node, the wafers designated for
any Persons other than the Purchaser). The Manufacturing Plan covering [***] and
in effect as of the Agreement Date has been agreed by the Parties.
3.2    Annual Calendar. Prior to the beginning of each Fiscal Year, the Parties
shall establish a planning calendar for such Fiscal Year (each, an “Annual
Calendar”) that sets forth key planning and finance dates during such Fiscal
Year, which may include the dates on which the Parties will (a) deliver the
Monthly Planning Statements (or the components thereof), the Demand Forecasts,
the Responses to Forecast, the Operational Reports, the Long Range Forecast, the
Preliminary Price Notices, the Purchase Orders and any other information that
may be agreed in writing by the Parties, and (b) hold the Quarterly Business
Reviews and Monthly Financial Reviews described in Section 3.14, provided that
such dates shall be consistent with this Article 3 and Article 4, as applicable,
and shall generally be consistent with the Purchaser’s internal planning
calendar for such Fiscal Year. In addition, the Annual Calendar may reflect the
dates during such Fiscal Year on which the Parties will be required by this
Agreement to deliver Purchaser Pricing Reports, Inotera Financial Reports and
Final Invoices. The Parties may alter the dates described in an Annual Calendar
at any time, provided that such altered dates are consistent with this Article 3
and Article

DLI-266520155v1
17

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

4, as applicable, and are agreed in writing by the Parties. The Annual Calendar
for 2015 and in effect as of the Agreement Date has been agreed by the Parties.
3.3    Monthly Planning Statement. Each Fiscal Month, Inotera shall deliver to
the Purchaser one or more statements (collectively for each Fiscal Month, a
“Monthly Planning Statement”) setting forth (a) for each Process Node, the
anticipated Committed Purchaser Manufacturing Capacity for each of the next
[***] Fiscal Months (or such other period as may be agreed in writing by the
Parties) taking into account, among other things, [***] that were included in
the Response to Forecast delivered in the prior Fiscal Month, (b) for each
Design ID, the [***] as the Purchaser and Inotera may agree in writing for such
Design ID for each of the next [***] Fiscal Months and (c) the Boundary
Conditions applicable to the next [***] Fiscal Months.
3.4    Demand Forecast. Following receipt of a Monthly Planning Statement as
contemplated by Section 3.3, the Purchaser shall deliver to Inotera a written
non-binding forecast of the Purchaser’s demand (each, a “Demand Forecast”) for
the [***] Fiscal Months (or such other period as may be agreed in writing by the
Parties) covered by such Monthly Planning Statement. Each Demand Forecast (a)
shall include the total number of Conforming Wafers (broken out by Design ID and
Process Node), Pre-Qual Engineering Wafers (broken out by Design ID and Process
Node) and Pre-Qual Production Wafers (broken out by Design ID and Process Node)
requested by the Purchaser for the period covered by such Demand Forecast
(broken out weekly) and (b) shall be consistent with the Committed Purchaser
Manufacturing Capacity and Boundary Conditions set forth in the Monthly Planning
Statement to which it relates.
3.5    Response to Forecast; Resolution of Conflicts. Following receipt of a
Demand Forecast as contemplated by Section 3.4, Inotera shall deliver to the
Purchaser a written response that, so long as such Demand Forecast delivered by
the Purchaser is consistent with the Committed Purchaser Manufacturing Capacity
and Boundary Conditions set forth in the Monthly Planning Statement to which it
relates, indicates Inotera commits to supply Conforming Wafers, Pre-Qual
Engineering Wafers and Pre-Qual Production Wafers based on such Demand Forecast
(each, a “Response to Forecast”). In preparing any Response to Forecast at any
time the Committed Purchaser Manufacturing Capacity is less than 100% of the
Manufacturing Capacity of Inotera at the Inotera Fab, if there is a conflict
with respect to the manufacture of wafers for the Purchaser pursuant to this
Agreement and the manufacture of wafers or other products for any other Person,
such conflict shall be resolved [***] and the manufacture of wafers for the
[***].
3.6    Changes to Demand Forecast. The Purchaser may deliver to Inotera an
adjusted Demand Forecast for any purpose, including to reduce the number of
Conforming Wafers, Pre-Qual Engineering Wafers and Pre-Qual Production Wafers to
be delivered to the Purchaser, to increase the number of Conforming Wafers,
Pre-Qual Engineering Wafers and Pre-Qual Production Wafers to be delivered to
the Purchaser (if less than all of the Committed Purchaser Manufacturing
Capacity was previously included in the Demand Forecast) and to change the
Design ID mix of Conforming Wafers, Pre-Qual Engineering Wafers and Pre-Qual
Production Wafers to be manufactured utilizing a particular Process Node, at any
time until [***] prior to the scheduled loading of the wafers affected by
adjustments reflected in the adjusted Demand Forecast. In such event, Inotera
shall

DLI-266520155v1
18

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

deliver to the Purchaser a revised Response to Forecast that, so long as such
adjustments are consistent with the Committed Purchaser Manufacturing Capacity
and the Boundary Conditions set forth in the most recently delivered Monthly
Planning Statement, indicates Inotera commits to supply Conforming Wafers,
Pre-Qual Engineering Wafers and Pre-Qual Production Wafers based on such
adjustments.
3.7    [***]. Notwithstanding anything herein to the contrary, if, for any
particular Delivery Month, Inotera [***] to the Purchaser (at the Purchaser’s
request pursuant to a [***] delivered in the Fiscal Month prior to such Delivery
Month) [***] for such Delivery Month set forth in the [***] delivered in the
Fiscal Month prior to such Delivery Month, the [***] of Non-HMC Conforming
Wafers and Non-HMC Pre-Qual Production Wafers delivered in such Delivery Month
shall [***]. Any such “[***]” shall be calculated in accordance with Schedule
3.7.
3.8    [***].
(a)    Notwithstanding anything herein to the contrary, if, at any time, Inotera
reasonably expects to [***] as a result of manufacturing Non-HMC Conforming
Wafers and Non-HMC Pre-Qual Production Wafers utilizing [***] for delivery to
the Purchaser in a particular Delivery Month based on [***] of the Committed
Purchaser Manufacturing Capacity for such [***] for such Delivery Month set
forth in the most recently delivered Monthly Planning Statement, Inotera may
deliver to the Purchaser a written notice (each, a “[***] Notice”) setting forth
the [***] Inotera reasonably believes it can [***] the Purchaser in such
Delivery Month utilizing [***] and not cause a [***] (the [***] in its most
recently delivered [***] for such Delivery Month and the [***] set forth in a
[***] Notice, the “[***]”).
(b)    Within [***] of receipt of a [***] Notice, the Purchaser may deliver to
Inotera a written notice (a “[***] Notice”) setting forth (i) the [***] to be
[***] utilizing [***] described in the [***] Notice that the Purchaser [***] in
the applicable Delivery Month that are [***] of the [***] [***] set forth in the
applicable [***] Notice (such [***], the “[***]”) and (ii) the Purchaser’s [***]
to Inotera the [***] with respect to the [***]. If the Purchaser delivers such a
written notice, then the [***] with respect to the [***] shall be [***] in the
Delivery Month in which such [***] are delivered to the Purchaser.
(c)    Notwithstanding anything herein to the contrary, if Inotera has delivered
a [***] Notice with respect to a particular [***] for a particular Delivery
Month, Inotera shall [***] the Purchaser in such Delivery Month the [***] as are
set forth in such [***] Notice, as adjusted for the [***].
(d)    For any Delivery Month after a Delivery Month for which the [***] for a
particular [***] has been [***] of Non-HMC Conforming Wafers and Non-HMC
Pre-Qual Production Wafers [***] the Purchaser, Inotera shall [***] of Non-HMC
Conforming Wafers and Non-HMC Pre-Qual Production Wafers [***] the Purchaser
[***] to the [***] for such [***] until the [***] of Non-HMC Conforming Wafers
and Non-HMC Pre-Qual Production Wafers [***] the

DLI-266520155v1
19

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Purchaser [***] for such [***] of Non-HMC Conforming Wafers and Non-HMC Pre-Qual
Production Wafers [***] the Purchaser.
(e)    “[***]” and “[***]” shall be calculated in accordance with Schedule 3.8.
3.9    [***] of Loading. If any Operational Report includes (a) a notification
described in Section 3.12(e) with respect to DRAM Products of a particular
Design ID and, during the Quarterly Business Review in which such Operational
Report is discussed, the Purchaser informs Inotera that the Purchaser is [***]
to include in [***] of Conforming Wafers and Pre-Qual Production Wafers of DRAM
Products of such Design ID to [***] for such Design ID, or (b) a notification
described in Section 3.12(f), then the [***] of Non-HMC Conforming Wafers,
Non-HMC Pre-Qual Production Wafers, HMC Conforming Wafers and HMC Pre-Qual
Production Wafers [***] the Purchaser in the Delivery Month next following the
Delivery Month in which such Quarterly Business Review occurs shall [***] (the
“[***]”) equal to the sum of (a) the product of (i) the [***] associated with
such Design ID ([***] (A) included in the [***] for any [***] of such Design ID
[***], (B) [***] by Micron or the Purchaser pursuant to [***], and (C) the
[***]), multiplied by (ii) the quotient of (A) the difference of (I) [***],
minus (II) the [***] of such Design ID that were or will be [***] during such
[***], divided by (B) [***], plus (b) the [***].  Notwithstanding anything above
to the contrary, DRAM Products that are manufactured utilizing [***] shall be
deemed to be [***] for purposes of [***] described in this Section 3.9.
3.10    [***] Statements. At least [***], Inotera shall deliver to the Purchaser
a statement setting forth the number of Conforming Wafers, Pre-Qual Engineering
Wafers and Pre-Qual Production Wafers (in each case, by Design ID) that are
anticipated to be delivered to the Purchaser during each of the next [***]. In
addition, at least [***], Inotera shall deliver to the Purchaser a statement
setting forth:
(a)    by Design ID, the number of Conforming Wafers, Pre-Qual Engineering
Wafers, Pre-Qual Production Wafers, and Non-Conforming Wafers that were
delivered to the Purchaser in the immediately preceding [***];
(b)    by Design ID, the Die Yield, Line Yield and Cycle-Time in the immediately
preceding [***]; and
(c)    such other Performance Criteria as the Purchaser and Inotera may agree in
writing.
3.11    Inotera Financial Report. Within [***] days after the end of each
Delivery Month in the case of [***] and within [***] Business Days after the end
of each Delivery Month in the case of [***] (or such other number of days as may
be agreed in writing by the Parties), Inotera shall deliver to the Purchaser a
report (each, a “Inotera Financial Report”) which shall include:

DLI-266520155v1
20

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(a)    a detailed calculation, by Design ID, of Final Price for the Delivery
Month just ended;
(b)    if the Final Price for the Delivery Month just ended includes any [***]
Payment Amount, a detailed calculation of the [***] Payment Amount for such
Delivery Month;
(c)    if the Final Price for the Delivery Month just ended includes any [***],
a detailed calculation of the [***] for such Delivery Month;
(d)    if the Final Price for the Delivery Month just ended includes any [***],
a detailed calculation, by Process Node, of any [***] for such Delivery Month;
(e)    if the Final Price for the Delivery Month just ended includes any [***],
a detailed calculation, by Process Node, of any [***] for such Delivery Month;
(f)    if the Final Price for the Delivery Month just ended includes any [***],
a detailed calculation, by Design ID, of any [***] for such Delivery Month;
(g)    if the Final Price for the Delivery Month just ended includes [***], a
detailed calculation, by Design ID, of any [***] for such Delivery Month;
(h)    if [***] were delivered in the Delivery Month just ended, a detailed
calculation, by Design ID, of the [***];
(i)    if [***] are delivered in the Delivery Month just ended, a detailed
calculation, by Design ID, of the [***]; and
(j)    other financial information regarding Inotera for the Delivery Month just
ended, consistent with the financial information regarding Inotera that has been
historically provided to Micron by Inotera.
The Purchaser will not use or disclose Inotera Financial Reports, or the
contents thereof, received by the Purchaser in contravention of any Applicable
Law.
3.12    Operational Report. Each Fiscal Quarter, Inotera shall deliver to the
Purchaser a report with respect to the Fiscal Quarter just ended (the
“Operational Report”), which shall include:
(a)    a comparison of [***] relative to the [***] delivered in the [***]
immediately prior to the [***], together with a comparison of [***] for the next
[***] relative to the [***];

DLI-266520155v1
21

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(b)    a summary of the [***], a summary of [***], including [***], [***] and
other indicators that may evidence or impact [***], and a description of any
[***];
(c)    a description of [***] or other [***], including any [***], [***] or
other indicator, summarized pursuant to Section 3.12(b);
(d)    a description of [***] (and [***], if known) that are not reflected in
[***] which may [***];
(e)    a notification that, since the date of the last Operational Report, the
[***] to include Conforming Wafers and Pre-Qual Production Wafers of a
particular Design ID in [***] such that, during [***], the sum of (i) the [***]
reflected in the [***] to be delivered [***] in such [***], plus (ii) the [***]
during such [***], is [***] (the “[***]”); provided, however, that,
notwithstanding anything above to the contrary, DRAM Products that are
manufactured utilizing [***] shall be deemed to be [***] for purposes of [***]
described in this Section 3.9; and
(f)    a notification that, since the date of the last Operational Report, the
[***].
3.13    Purchaser Pricing Report. Each Fiscal Month, as soon as practicable, but
no later than [***] days (or such other number of days as may be agreed in
writing by the Parties) after the end of the Fiscal Month just ended, the
Purchaser shall deliver to Inotera a report (each, a “Purchaser Pricing
Report”), which shall include (a) the detailed calculation of the Price of
Non-HMC Conforming Wafers, Non-HMC Pre-Qual Production Wafers, HMC Conforming
Wafers and HMC Pre-Qual Production Wafers delivered in the Fiscal Month just
ended and (b) the detailed calculation of the [***] Payment Amount for the
Fiscal Month just ended. The “[***] Payment Amount” for any Fiscal Month shall
be calculated in accordance with Schedule 3.13. Inotera will not use or disclose
the Purchaser Pricing Reports, or the contents thereof, received by Inotera in
contravention of any Applicable Law.
3.14    Periodic Performance Reviews.
(a)    Inotera shall hold quarterly meetings (each, a “Quarterly Business
Review”) with the Purchaser, the primary purposes of which shall be to review
and discuss the most recent Operational Report and the Performance Criteria and
to mutually agree on operational adjustments if necessary.
(b)    The Purchaser and Inotera shall hold monthly meetings (each, a “Monthly
Financial Review”) to review and discuss (i) at the election of the Purchaser,
the Inotera Financial Reports received by the Purchaser since the last such
meeting, and (ii) at the election of Inotera, the Purchaser Pricing Reports
delivered by the Purchaser since the last such meeting.
3.15    Long Range Forecast. Each Fiscal Year, the Purchaser will provide
Inotera, for its review and comment, with a written non-binding forecast (each,
a “Long Range Forecast”) of the Purchaser’s demand for Conforming Wafers and
Pre-Qual Production Wafers for the next [***].

DLI-266520155v1
22

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

3.16    Restrictions on Access to Pricing Information; Nonsolicitation of
Segregated Employees.
(a)    Inotera shall prevent any Person that is not a Segregated Employee from
obtaining access to the pricing information (including the Purchaser Pricing
Reports and the Inotera Financial Reports), or the data from which pricing
information is derived from, delivered to, or created by, Inotera under this
Agreement, except (i) as the Parties may otherwise agree in writing, (ii) as may
be required by legal process under Applicable Law, and (iii) that Inotera may
provide (A) the Purchaser with Inotera Financial Reports, Preliminary Price
Notices, Pro Forma Invoices, Final Invoices and the data from which such Inotera
Financial Reports, Preliminary Price Notices, Pro Forma Invoices or Final
Invoices are derived, (B) any independent Third Party auditor acting as
contemplated by Section 6.4 with such information as such auditor may request
that is reasonably relevant to the applicable inspection and audit, and (C)
Inotera’s independent outside auditors with such information as such auditor may
reasonably request in connection with its audit of Inotera’s financial
statements and other statutory audit requirements (the items in clauses (i),
(ii) and (iii) being referred to as the “Permitted Disclosures”). Without
limiting the generality of the foregoing, Inotera shall (x) develop, maintain,
implement and enforce policies that (A) prohibit all Segregated Employees from
disclosing, or allowing disclosure of, pricing information (including the
Purchaser Pricing Reports and the Inotera Financial Reports) to Persons that are
not Segregated Employees, other than the Permitted Disclosures and (B) require
all Segregated Employees to store all physical files related to pricing
(including the Purchaser Pricing Reports and the Inotera Financial Reports) in
secure locations that are not accessible by non-Segregated Employees, (y)
segregate the office space of the Segregated Employees from other employees of
Inotera, and (z) maintain all electronic files containing pricing information
(including the Purchaser Pricing Reports and the Inotera Financial Reports) in
confidential password protected files. The Purchaser shall not take any action
that reasonably should be expected to cause Inotera to violate this Section
3.16.
(b)    Even if permitted under Section 9.4 of the Joint Venture Agreement, the
Purchaser shall not, and shall cause its Affiliates not to, directly or
indirectly recruit, solicit or hire, or make arrangements to recruit, solicit or
hire, any current or former Segregated Employee during the Restriction Period.
ARTICLE 4
PURCHASE AND SALE OF PRODUCTS
4.1    Product Quantity. The Purchaser shall purchase from Inotera all of the
Conforming Wafers manufactured in response to the Purchaser’s Demand Forecasts
(including any adjusted Demand Forecast) in accordance with Article 3 and the
Purchase Orders (including any revised or supplemented Purchase Order) accepted
in accordance with this Article 4.

DLI-266520155v1
23

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

4.2    Non-Conforming Wafers. At the direction and option of the Purchaser,
Inotera shall deliver to the Purchaser all Non-Conforming Wafers produced by
Inotera (a) from wafers designated from Wafer Start for the Purchaser in
accordance with Section 2.4 and (b) in the case of Shared Design ID Wafers, the
portion thereof allocated to the Purchaser in accordance with Section 2.4.
4.3    Pre-Qual Engineering Wafers and Pre-Qual Production Wafers.
Notwithstanding anything herein to the contrary, to the extent requested in any
Purchase Order placed, or any change order to a Purchase Order issued, by the
Purchaser, Inotera shall manufacture and deliver Pre-Qual Engineering Wafers
and/or Pre-Qual Production Wafers in lieu of Conforming Wafers; provided,
however, that in no event shall Inotera be obligated to load any HMC Pre-Qual
Wafers unless and until the Parties have first negotiated and agreed as to how
to calculate the Price of HMC Pre-Qual Wafers as contemplated by Section 5.1(d).
Inotera shall promptly provide the Purchaser with full access to all data the
Purchaser reasonably requests relating to Pre-Qual Engineering Wafers and
Pre-Qual Production Wafers that are being manufactured by Inotera for the
Purchaser.
4.4    Preliminary Price Notices; Placement of Purchase Orders.
(a)    Prior to each Fiscal Month, Inotera shall deliver to the Purchaser a
notice (each, a “Preliminary Price Notice”), which shall set forth the
Preliminary Price for Conforming Wafers, the Preliminary Price for Pre-Qual
Production Wafers, the Preliminary Price for Pre-Qual Engineering Wafers, and
the Preliminary Price for Non-Conforming Wafers for such Fiscal Month. The
Parties hereby acknowledge that Inotera has timely delivered to the Purchaser a
Preliminary Price Notice for the Fiscal Month commencing on the Effective Date.
(b)    Prior to each Fiscal Month, following receipt of the Preliminary Price
Notice with respect to such Fiscal Month, the Purchaser shall place a
non-cancelable blanket purchase order (each such order, a “Purchase Order”) for
the quantity, by Design ID, of Conforming Wafers, Pre-Qual Engineering Wafers,
Pre-Qual Production Wafers, and Non-Conforming Wafers to be supplied to it by
Inotera in the upcoming Fiscal Month. The Parties hereby acknowledge that the
Purchaser has timely delivered to Inotera Purchase Orders for the Fiscal Month
commencing on the Effective Date. The Purchaser may issue change orders to the
Purchase Orders the Purchaser delivers to reflect changes in its Demand
Forecasts in accordance with Article 3. The Purchaser may also elect to place
with Inotera out-of-cycle Purchase Orders of Conforming Wafers, Pre-Qual
Engineering Wafers, Pre-Qual Production Wafers, or Non-Conforming Wafers on an
as-needed basis. Any Purchase Order placed, or change order to a Purchase Order
issued, hereunder shall be in writing and delivered via e-mail or facsimile
transmission. The terms and conditions of this Agreement supersede the terms and
conditions contained in any sales or purchase documentation provided in
connection herewith unless expressly agreed otherwise in a writing signed by the
Parties. Any Purchase Order for wafers may be placed in the name of the
Purchaser, Micron or any other Affiliate of the Purchaser that is a direct or
indirect wholly owned Subsidiary of Micron. If a Purchase Order for wafers is
placed in a name of an Affiliate of the Purchaser, the Purchaser shall be
jointly and severally liable with such Affiliate for any and all
responsibilities and obligations under the Purchase Order.

DLI-266520155v1
24

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

4.5    Content of Purchase Orders. Each Purchase Order shall specify the
following items:
(a)    the Purchase Order number;
(b)    the Design ID of each Conforming Wafer, Pre-Qual Engineering Wafer,
Pre-Qual Production Wafers and Non-Conforming Wafer;
(c)    by Design ID, the forecasted quantity for the Fiscal Month of Conforming
Wafers, Pre-Qual Engineering Wafers, Pre-Qual Production Wafers, and
Non-Conforming Wafers;
(d)    the Preliminary Price for each Conforming Wafer, the Preliminary Price
for each Pre-Qual Production Wafers, the Preliminary Price for each Pre-Qual
Engineering Wafer, and the Preliminary Price for each Non-Conforming Wafer;
(e)    the aggregate Preliminary Price for all Conforming Wafers ordered, the
Preliminary Price for all Pre-Qual Production Wafers ordered, the aggregate
Preliminary Price for all Pre-Qual Engineering Wafers ordered, and the aggregate
Preliminary Price for all Non-Conforming Wafers ordered;
(f)    special instructions for manufacturing Pre-Qual Engineering Wafers and
Pre-Qual Production Wafers, if any; and
(g)    other terms (if any).
Inotera shall not use or disclose the Purchaser Orders, or the contents thereof,
received by Inotera in contravention of any Applicable Law.
4.6    Acceptance of Purchase Order. Each Purchase Order that (a) corresponds to
the then most-recently delivered Response to Forecast (and any revised Response
to Forecast) delivered in accordance with Article 3 and (b) is otherwise free of
errors, shall be deemed accepted by Inotera upon receipt and shall be binding on
Inotera and the Purchaser to the extent not inconsistent with the then
most-recently delivered Response to Forecast (or revised Response to Forecast).
4.7    Output Shortfall; Excess Output.
(a)    Inotera shall immediately notify the Purchaser in writing of any
inability to meet a Purchase Order commitment to the Purchaser. In such an
event, the Purchaser shall accept delivery of such lesser quantities Inotera is
able to ship and issue to Inotera a revised Purchase Order to account for such
shortfall.

DLI-266520155v1
25

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(b)    Inotera shall immediately notify the Purchaser in writing if the output
to be purchased by the Purchaser under this Agreement will exceed, for any
Design ID, the quantity of Conforming Wafers, Pre-Qual Production Wafers or
Non-Conforming Wafers contained in the Purchaser’s Purchase Order. In such an
event, the Purchaser shall accept delivery of the additional quantities and
issue to Inotera a supplementary Purchase Order to cover such excess.
4.8    Taxes.
(a)    General. All sales, use and other transfer taxes imposed directly on or
solely as a result of the supplying of Conforming Wafers, Pre-Qual Engineering
Wafers, Pre-Qual Production Wafers, and Non-Conforming Wafers to the Purchaser
and the payments therefor provided herein shall be stated separately on
Inotera’s Invoices, collected from the Purchaser and shall be remitted by
Inotera to the appropriate tax authority (“Recoverable Taxes”), unless the
Purchaser provides valid proof of tax exemption prior to the effective date of
the transfer of the Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, and Non-Conforming Wafers or otherwise as permitted by
Applicable Law prior to the time Inotera is required to pay such taxes to the
appropriate tax authority. When property is delivered and/or services are
provided, or the benefit of services occurs, within jurisdictions in which
collection of taxes from the Purchaser and remittance of taxes by Inotera is
required by Applicable Law, Inotera shall have sole responsibility for payment
of said taxes to the appropriate tax authorities. In the event such taxes are
Recoverable Taxes and Inotera does not collect tax from the Purchaser, or pay
such taxes to the appropriate governmental entity on a timely basis, and is
subsequently audited by any tax authority, liability of the Purchaser shall be
limited to the tax assessment for such Recoverable Taxes with no reimbursement
for penalty or interest charges or other amounts incurred in connection
therewith. Notwithstanding anything herein to the contrary, taxes other than
Recoverable Taxes shall not be reimbursed by the Purchaser, and each of the
Purchaser and Inotera is responsible for its own respective income taxes
(including franchise and other taxes based on net income or a variation
thereof), taxes based upon gross revenues or receipts and taxes with respect to
general overhead, including business and occupation taxes, and such taxes shall
not be Recoverable Taxes.
(b)    Withholding Taxes. In the event that the Purchaser is prohibited by
Applicable Law from making payments to Inotera unless the Purchaser deducts or
withholds taxes therefrom and remits such taxes to the local taxing
jurisdiction, then the Purchaser shall duly withhold and remit such taxes and
shall pay to Inotera the remaining net amount after the taxes have been
withheld. Such taxes shall not be Recoverable Taxes and the Purchaser shall not
reimburse Inotera for the amount of such taxes withheld.
4.9    Invoicing; Payment.
(a)    Along with each delivery of Conforming Wafers, Pre-Qual Production
Wafers, Pre-Qual Engineering Wafers, or Non-Conforming Wafers to the Purchaser,
Inotera shall invoice the Purchaser for the aggregate Preliminary Price of the
Conforming Wafers, Pre-Qual Production Wafers, Pre-Qual Engineering Wafers, and
Non-Conforming Wafers contained in such delivery (a “Pro Forma Invoice”).

DLI-266520155v1
26

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(b)    No later than [***] days (or such other number of days as may be agreed
in writing by the Parties) prior to the end of each Delivery Month, the
Purchaser shall deliver to Inotera a statement setting forth such Purchaser’s
estimates of the Price of Non-HMC Conforming Wafers and Non-HMC Pre-Qual
Production Wafers and the [***] Payment Amount for such Delivery Month.
(c)    Within [***] Business Days (or such other number of days as may be agreed
in writing by the Parties) after the delivery of the Purchaser Pricing Report,
Inotera shall issue to the Purchaser a final invoice (a “Final Invoice”), which
shall include a debit equal to the Price True-Up Amount for such Delivery Month,
if positive, and a credit equal to the Price True-Up Amount for such Delivery
Month, if negative.
(d)    Except as otherwise specified in this Agreement, (i) the Purchaser shall
pay Inotera for the amounts due and owing by, and duly invoiced in a Pro Forma
Invoice to, the Purchaser within [***] days following delivery to the Purchaser
of the Final Invoice for the Delivery Month in which such Pro Forma Invoice was
delivered or, if longer, within [***] days following the end of such Delivery
Month and (ii) the Purchaser shall pay the Inotera for the amount due and owing
by, and duly invoiced in a Final Invoice to, the Purchaser within [***] days
following the delivery to the Purchaser of such Final Invoice or, if later,
within [***] days following the end of the Delivery Month covered thereby. All
amounts owed under this Agreement are stated, calculated and shall be paid in
United States Dollars.
(e)    If the Purchaser does not pay Inotera for the amounts due under this
Agreement, interest on the unpaid invoiced amounts will be calculated and
imposed at the rate of [***] percent ([***]%) per annum, on a daily basis, from
the due date until the payment is made, provided that, if the due date falls on
a day that is not a Business Day, the payment shall be due by the next
succeeding Business Day. However, if the Purchaser and Inotera do not agree on
the payment amount of any Pro Forma Invoice or Final Invoice, interest on the
disputed amount will not be imposed and accrued under this Agreement.
(f)    In the event that the Purchaser reasonably disputes any Pro Forma Invoice
or Final Invoice provided hereunder, the Purchaser and Inotera will each appoint
an officer who will use their best efforts to resolve such dispute within [***]
days following the date such dispute is raised by the Purchaser. If such
officers are unable to resolve the dispute in the given [***] days, then the
dispute shall be submitted to the respective presidents of the Purchaser and
Inotera for resolution.
(g)    If this Agreement has terminated or is terminating so that the Purchaser
will not be able to use any credits issued by Inotera to the Purchaser, Inotera
will promptly pay to the Purchaser an amount equal to such credits.

DLI-266520155v1
27

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

4.10    Payment to Subcontractors. Inotera shall be responsible for, and shall
hold the Purchaser harmless from and against, any and all payments to the
vendors or subcontractors Inotera utilizes in the performance of this Agreement.
4.11    Title; Risk of Loss. Title to, and risk of loss of, Conforming Wafers,
Pre-Qual Engineering Wafers, Pre-Qual Production Wafers, and Non-Conforming
Wafers shall pass to the Purchaser [***] according to Incoterms 2010, as
amended, provided that Inotera will [***], and will assist the Purchaser in
[***] of, the Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, and Non-Conforming Wafers in a manner consistent with past
practices.
4.12    Packaging. All shipment packaging of the Conforming Wafers, Pre-Qual
Engineering Wafers, Pre-Qual Production Wafers, and Non-Conforming Wafers shall
be in conformance with the applicable Specifications, the Purchaser’s reasonable
instructions and general industry standards, and shall be resistant to damage
that may occur during transportation. Marking on the packages shall be made by
Inotera in accordance with the Purchaser’s reasonable instructions.
4.13    Shipment. All Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, and Non-Conforming Wafers shall be prepared for shipment in a
manner that: (a) follows good commercial practice; (b) is acceptable to common
carriers for shipment at the lowest rate; and (c) is adequate to ensure safe
arrival. Inotera shall mark all containers with (i) necessary lifting, handling
and shipping information; (ii) Purchase Order number; (iii) date of shipment;
and (iv) the name of the Purchaser. If no instructions are given, Inotera shall
select the most price effective carrier, given the time constraints known to
Inotera. In no event shall Inotera be obligated to maintain any significant
inventory for the Purchaser.
4.14    Customs Clearance. Upon the Purchaser’s request, Inotera shall promptly
provide the Purchaser with a statement of origin, and applicable customs
documentation, for Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, and Non-Conforming Wafers wholly or partially manufactured
outside of the country of import.
ARTICLE 5
PRICING
5.1    Price.
(a)    The “Price” of each Non-HMC Conforming Wafer of a particular Design ID in
any particular Delivery Month shall be calculated in accordance with Schedule
5.1.
(b)    The “Price” of each Non-HMC Pre-Qual Production Wafer delivered to the
Purchaser during a Delivery Month shall be equal to the Baseline Price Per Wafer
as stated in Schedule 5.1.

DLI-266520155v1
28

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(c)    The “Price” of each HMC Conforming Wafer shall be calculated on a [***]
basis to be negotiated in good faith by the Parties prior to Inotera loading any
HMC Wafers.
(d)    The “Price” of each HMC Pre-Qual Production Wafer shall be calculated on
a [***] basis to be negotiated in good faith by the Parties prior to Inotera
loading any HMC Wafers.
5.2    Final Price. The “Final Price” of each Non-HMC Conforming Wafer, Non-HMC
Pre-Qual Production Wafer, HMC Conforming Wafer and HMC Pre-Qual Production
Wafer of a particular Design ID in any particular Delivery Month shall equal the
quotient of (i) the sum of (A) the aggregate Price of all Non-HMC Conforming
Wafers of such Design ID delivered to the Purchaser in such Delivery Month
calculated in accordance with Section 5.1(a), plus (B) the aggregate Price of
all Non-HMC Pre-Qual Production Wafers of such Design ID delivered to the
Purchaser in such Delivery Month calculated in accordance with Section 5.1(b),
plus (C) the aggregate Price of all HMC Conforming Wafers of such Design ID
delivered to the Purchaser in such Delivery Month calculated in accordance with
Section 5.1(c), plus (D) the aggregate Price of all HMC Pre-Qual Production
Wafers of such Design ID delivered to the Purchaser in such Delivery Month
calculated in accordance with Section 5.1(d), [***] (E) the [***] Payment Amount
for such Design ID for such Delivery Month [***], if any, [***] (F) the [***]
for such Design ID for such Delivery Month, if any, [***] (G) the [***] for such
Design ID for such Delivery Month, if any, [***] (H) the [***] for such Design
ID in such Delivery Month, if any, [***] (I) the [***] for such Design ID for
such Delivery Month, if any, [***] (J) the [***] for such Design ID for such
Delivery Month, if any, [***] (K) the [***], for such Design ID for such
Delivery Month, divided by (ii) the sum of (a) the number of Non-HMC Conforming
Wafers of such Design ID delivered to the Purchaser in such Delivery Month plus
(b) the number of Non-HMC Pre-Qual Production Wafers of such Design ID delivered
to the Purchaser in such Delivery Month plus (c) the number of HMC Conforming
Wafers of such Design ID delivered to the Purchaser in such Delivery Month plus
(d) the number of HMC Pre-Qual Production Wafers of such Design ID delivered to
the Purchaser in such Delivery Month.
5.3    Price of Pre-Qual Engineering Wafers. The price of each Pre-Qual
Engineering Wafer delivered to the Purchaser during a Delivery Month shall be
calculated in accordance with Schedule 5.2.
5.4    Price of Non-Conforming Wafers. Any Non-Conforming Wafers delivered to
the Purchaser during a Delivery Month shall be [***].
ARTICLE 6
VISITATIONS; FACTORY REPRESENTATIVES; AUDITS
6.1    Visits. Inotera shall accommodate the Purchaser’s reasonable requests for
visits to the Inotera Fab and for meetings for the purpose of reviewing
performance of production of Conforming Wafers, including requests for further
information and assistance in troubleshooting performance issues.

DLI-266520155v1
29

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

6.2    Factory Representatives. At Micron’s or the Purchaser’s request, Inotera
will designate at least one (1) of its employees with sufficient knowledge of
and expertise in the operation of the Inotera Fab to interface with Micron and
the Purchaser in a manner consistent with past practices. This employee will be
the central point of contact for communication between Micron and the Purchaser,
on the one hand, and Inotera, on the other hand, in regards to operational
issues at the Inotera Fab arising out of the performance of this Agreement. Such
employee will enter into such confidentiality agreement as Micron or the
Purchaser may reasonably require.
6.3    Audit. The Purchaser’s representatives and key customer representatives,
upon the Purchaser’s request, shall be allowed to visit the Inotera Fab during
normal working hours upon reasonable advance written notice to Inotera for the
purposes of monitoring production processes and compliance with any requirements
set forth in this Agreement applicable to the supply to the Purchaser and the
applicable Specifications. Upon completion of the audit, Inotera and the
Purchaser shall agree to an audit closure plan, to be documented in the audit
report issued by the Purchaser.
6.4    Financial Audit.
(a)    Micron and the Purchaser reserve the right to have Inotera’s books and
records related to pricing of the Conforming Wafers, Pre-Qual Production Wafers,
(including each of the components of Final Price) and Pre-Qual Engineering
Wafers purchased by the Purchaser during both the then current Fiscal Year and
the prior Fiscal Year inspected and audited not more than [***] during any
Fiscal Year to ensure compliance with Article 3 and Article 5. Such audit shall
be performed, at the expense of Micron or the Purchaser, by an independent Third
Party auditor acceptable to the Parties. Micron and the Purchaser shall provide
[***] days advance written notice to Inotera of their desire to initiate an
audit, and the audit shall be scheduled so that it does not adversely impact or
interrupt Inotera’s business operations. If the audit reveals any material
discrepancies, the Purchaser or Inotera shall reimburse the other, as
applicable, for any material discrepancies within [***] days after completion of
the audit. The nature and extent of the discrepancies identified by the audit
shall be reported to the Parties. Notwithstanding the foregoing, auditor reports
shall not disclose pricing, or terms of purchase, for any purchases of materials
or equipment by Inotera, absent written agreement from the respective legal
counsel of the Parties. If any audit reveals a material discrepancy requiring a
payment by Inotera, Micron and the Purchaser may increase the frequency of such
audits to [***] for the [***].
(b)    Inotera reserves the right to have the books and records of Micron and
the Purchaser related to the Purchaser Pricing Reports for both the then current
Fiscal Year and the prior Fiscal Year inspected and audited not more than [***]
during any Fiscal Year to ensure compliance with Article 5. Such audit shall be
performed, at Inotera’s expense, by an independent Third Party auditor
acceptable to the Parties. Inotera shall provide [***] days advance written
notice to Micron and the Purchaser of its desire to initiate an audit, and the
audit shall be scheduled so that it does not adversely impact or interrupt the
business operations of Micron or the Purchaser. If the audit reveals any
material discrepancies, the Purchaser or Inotera shall reimburse the other, as
applicable, for any material discrepancies within [***] days after completion of
the audit. The nature and extent of the discrepancies identified by the audit
shall be reported to the Parties. Notwithstanding the

DLI-266520155v1
30

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

foregoing, auditor reports shall not disclose (i) [***] for any [***] by Micron
or the Purchaser, (ii) the back end [***] costs of Micron or the Purchaser, or
(iii) the [***] Micron or the Purchaser, absent written agreement from the
respective legal counsel of the Parties. If any audit reveals a material
discrepancy requiring a payment by the Purchaser, Inotera may increase the
frequency of such audits to [***] for the [***].
(c)    Information regarding the pricing of the Conforming Wafers, Pre-Qual
Production Wafers, (including each of the components of Final Price) and
Pre-Qual Engineering Wafers purchased by the Purchaser and the Purchaser Pricing
Reports as to which audit rights under this Section 6.4 have expired shall be
deemed final and conclusive for all purposes (absent fraud or willful
misconduct), except to the extent that (i) an audit with respect thereto has
been commenced under this Section 6.4 prior to such expiration and (ii) the
process under this Section 6.4 has not been fully completed with respect to such
audit. The Parties acknowledge the possibility that an audit commenced pursuant
to this Section 6.4 for the then current Fiscal Year and the prior Fiscal Year
may not be completed prior to [***].
ARTICLE 7
WARRANTY; HAZARDOUS SUBSTANCES; DISCLAIMER
7.1    Warranties.
(a)    Conforming Wafers. Inotera makes the following warranties to the
Purchaser of Conforming Wafers hereunder regarding the Conforming Wafers
furnished to the Purchaser hereunder, which warranties shall survive any
delivery, inspection, acceptance, payment or resale of such Conforming Wafers:
(i)    such Conforming Wafers conform to all applicable Specifications;
(ii)    such Conforming Wafers are free from defects in materials and
workmanship; and
(iii)    Inotera has the necessary right, title and interest to such Conforming
Wafers, and, upon the sale of such Conforming Wafers to the Purchaser, such
Conforming Wafers shall be free of liens and encumbrances.
(b)    Pre-Qual Production Wafers. Inotera makes the following warranties to the
Purchaser of Pre-Qual Production Wafers hereunder regarding the Pre-Qual
Production Wafers furnished to the Purchaser hereunder, which warranties shall
survive any delivery, inspection, acceptance, payment or resale of such Pre-Qual
Production Wafers:

DLI-266520155v1
31

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(i)    such Pre-Qual Production Wafers are free from defects in materials and
workmanship based on material and end product specifications provided by Micron;
and
(ii)    Inotera has the necessary right, title and interest to such Pre-Qual
Production Wafers, and, upon the sale of such Pre-Qual Production Wafers to the
Purchaser, such Pre-Qual Production Wafers shall be free of liens and
encumbrances.
(c)    Pre-Qual Engineering Wafers and Non-Conforming Wafers. ALL PRE-QUAL
ENGINEERING WAFERS AND NON-CONFORMING WAFERS PROVIDED HEREUNDER ARE PROVIDED ON
AN “AS IS,” “WHERE IS” BASIS WITH ALL FAULTS AND DEFECTS WITHOUT WARRANTY OF ANY
KIND.
7.2    Warranty Claims. Within a period of time, not to exceed the lesser of the
actual warranty period applicable to the end customer for the DRAM Product at
issue or [***] months from the date of the delivery of the Conforming Wafers or
Pre-Qual Production Wafers at issue to the Purchaser, the Purchaser shall notify
Inotera if it believes that any Conforming Wafer or Pre-Qual Production Wafer
does not meet the warranty set forth in Section 7.1. The Purchaser shall return
such Conforming Wafer or Pre-Qual Production Wafer (or DRAM Product therefrom)
to Inotera as directed by Inotera. If a Conforming Wafer or Pre-Qual Production
Wafer is determined not to be in compliance with such warranty, then the
Purchaser shall be entitled to return such Conforming Wafer or Pre-Qual
Production Wafer (or DRAM Product therefrom) and receive a credit (or, if this
Agreement has terminated or is terminating so that it will not be able to use
such credit, a refund) equal to the sum of (a) any monies paid to Inotera by the
Purchaser in respect of such Conforming Wafer or Pre-Qual Production Wafer plus
(b) any out-of-pocket charges for shipping and handling reasonably incurred by
the Purchaser in connection with such Conforming Wafer or Pre-Qual Production
Wafer. THE FOREGOING REMEDY IS THE PURCHASER’S SOLE AND EXCLUSIVE REMEDY FOR
INOTERA’S FAILURE TO MEET ANY WARRANTY OF SECTION 7.1.
7.3    Inspections. The Purchaser may, upon reasonable advance written notice,
request samples of WIP designated to the Purchaser (whether individually as
contemplated by Section 2.4(b) or together with others as contemplated by
Section 2.4(a)) during production for purposes of determining compliance with
the requirements and applicable Specification(s) hereunder, provided that the
provision of such samples shall not materially impact Inotera’s performance
under the Manufacturing Plan or its ability to meet delivery requirements under
any accepted Purchase Order. Any samples provided hereunder shall be:
(a) limited in quantity to the amount reasonably necessary for the purposes
hereunder; (b) invoiced and paid for in accordance with Section 4.9; and (c)
included in any performance requirements. Inotera shall provide reasonable
assistance for the safety and convenience of the Purchaser in obtaining the
samples in such manner as shall not unreasonably hinder or delay Inotera’s
performance.

DLI-266520155v1
32

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

7.4    Hazardous Substances.
(a)    If Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual Production
Wafers, Non-Conforming Wafers or DRAM Products provided hereunder include
Hazardous Substances as determined in accordance with Applicable Law, Inotera
shall ensure that its employees, agents and subcontractors actually working with
such materials in providing the Conforming Wafers, Pre-Qual Engineering Wafers,
Pre-Qual Production Wafers, Non-Conforming Wafers or DRAM Products hereunder to
the Purchaser are trained in accordance with Applicable Law regarding the nature
of, and hazards associated with, the handling, transportation and use of such
Hazardous Substances.
(b)    To the extent required by Applicable Law, Inotera shall provide the
Purchaser with Material Safety Data Sheets (MSDS) either prior to or
accompanying any delivery of Conforming Wafers, Pre-Qual Engineering Wafers,
Pre-Qual Production Wafers, Non-Conforming Wafers or DRAM Products to the
Purchaser.
(c)    Inotera shall indemnify, defend and hold harmless the Purchaser from and
against any and all Indemnified Losses suffered or incurred by the Purchaser
based on, relating to, or arising under any Environmental Laws and related to
the manufacture of Conforming Wafers, Pre-Qual Engineering Wafers, Pre-Qual
Production Wafers, Non-Conforming Wafers or DRAM Products by Inotera.
7.5    Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS ARTICLE 7,
INOTERA HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY, SUITABILITY OR
FITNESS FOR ANY PARTICULAR PURPOSE, NON-INFRINGEMENT OR OTHERWISE, WITH RESPECT
TO THE CONFORMING WAFERS, PRE-QUAL ENGINEERING WAFERS, PRE-QUAL PRODUCTION
WAFERS, NON-CONFORMING WAFERS OR DRAM PRODUCTS PROVIDED UNDER THIS AGREEMENT. NO
WARRANTIES SHALL APPLY TO ANY OF THE CONFORMING WAFERS, PRE-QUAL ENGINEERING
WAFERS, PRE-QUAL PRODUCTION WAFERS, NON-CONFORMING WAFERS OR DRAM PRODUCTS THAT
HAVE BEEN REPAIRED OR ALTERED, EXCEPT AS AUTHORIZED BY INOTERA, OR WHICH ARE
SUBJECTED TO MISUSE, NEGLIGENCE, ACCIDENT OR ABUSE. NO WARRANTIES FOR CONFORMING
WAFERS, PRE-QUAL ENGINEERING WAFERS, PRE-QUAL PRODUCTION WAFERS, NON-CONFORMING
WAFERS OR DRAM PRODUCTS DELIVERED BY INOTERA TO THE PURCHASER SHALL APPLY TO ANY
WARRANTY CLAIM OR ISSUE OR DEFECT TO THE EXTENT CAUSED BY TECHNICAL MATERIALS
PROVIDED OR SPECIFIED BY, THROUGH OR ON BEHALF OF THE PURCHASER, INCLUDING
PRODUCT DESIGNS, TECHNOLOGY AND TEST PROGRAMS.

DLI-266520155v1
33

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ARTICLE 8
CONFIDENTIALITY; OWNERSHIP
8.1    Protection and Use of Confidential Information. All information provided,
disclosed or obtained by any Party in the performance of activities under this
Agreement shall be subject to all applicable provisions of the Micron/Inotera
Confidentiality Agreement. Furthermore, the terms and conditions of this
Agreement shall be considered “Confidential Information” under the
Micron/Inotera Confidentiality Agreement for which each Party is considered a
“Receiving Party” under such agreement. To the extent there is a conflict
between this Agreement and the Micron/Inotera Confidentiality Agreement, the
terms of this Agreement shall control.
8.2    Masks for DRAM Products. Any masks used by Inotera to manufacture DRAM
Products under this Agreement shall be based on DRAM Designs owned by Micron or
its Affiliates and shall be treated as “Confidential Information” of Micron
under the Micron/Inotera Confidentiality Agreement.
ARTICLE 9
INDEMNIFICATION
9.1    General Indemnity. Subject to Article 10:
(a)    Inotera shall indemnify, defend and hold harmless the Purchaser
Indemnified Parties from and against any and all Indemnified Losses based on, or
attributable to, any Third Party Claim, or threatened Third Party Claim,
resulting from the negligence, gross negligence or willful misconduct of Inotera
or any of its respective officers, directors, employees, agents or
subcontractors.
(b)    the Purchaser shall indemnify, defend and hold harmless Inotera from and
against any and all Indemnified Losses based on, or attributable to, any Third
Party Claim, or threatened Third Party Claim, wherein the Third Party alleges
that DRAM Products manufactured for and/or sold to the Purchaser by Inotera are
infringing intellectual property rights of such Third Party.
9.2    Indemnification Procedures.
(a)    Promptly after the receipt by any Purchaser Indemnified Party or Inotera
(an “Indemnified Party”) of a notice of any Third Party Claim that may be
subject to indemnification under Section 9.1, such Indemnified Party shall give
written notice of such Third Party Claim to the Party obligated to provide such
indemnification under Section 9.1 (an “Indemnifying Party”), stating in
reasonable detail the nature and basis of each allegation made in the Third
Party Claim and the amount of potential Indemnified Losses with respect to each
allegation, to the extent known, along with copies of the relevant documents
received by the Indemnified Party evidencing the Third Party Claim and the basis
for indemnification sought. Failure of the Indemnified Party to give such notice
shall not relieve the Indemnifying Party from liability on account of this
indemnification,

DLI-266520155v1
34

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

except if, and only to the extent that, the Indemnifying Party is actually
prejudiced by such failure or delay. Thereafter, the Indemnified Party shall
deliver to the Indemnifying Party, promptly after the Indemnified Party’s
receipt thereof, copies of all notices and documents (including court papers)
received by the Indemnified Party relating to the Third Party Claim. The
Indemnifying Party shall have the right to assume the defense of the Indemnified
Party with respect to such Third Party Claim upon written notice to the
Indemnified Party delivered within thirty (30) days after receipt of the
particular notice from the Indemnified Party. So long as the Indemnifying Party
has assumed the defense of the Third Party Claim in accordance herewith and
notified the Indemnified Party in writing thereof, (i) the Indemnified Party may
retain separate co-counsel, at its sole cost and expense, and participate in the
defense of the Third Party Claim, it being understood that the Indemnifying
Party shall pay all reasonable costs and expenses of counsel for the Indemnified
Party after such time as the Indemnified Party has notified the Indemnifying
Party of such Third Party Claim and prior to such time as the Indemnifying Party
has notified the Indemnified Party that it has assumed the defense of such Third
Party Claim, (ii) the Indemnified Party shall not consent to the entry of any
judgment or enter into any settlement with respect to a Third Party Claim
without the prior written consent of the Indemnifying Party (not to be
unreasonably withheld, conditioned or delayed) and (iii) the Indemnifying Party
shall not consent to the entry of any judgment or enter into any settlement with
respect to the Third Party Claim (other than a judgment or settlement that is
solely for money damages and is accompanied by a release of all indemnifiable
claims against the Indemnified Party) without the prior written consent of the
Indemnified Party (not to be unreasonably withheld, conditioned or delayed).
(b)    Equitable Remedies. In the case of any Third Party Claim where the
Indemnifying Party reasonably believes that it would be appropriate to settle
such Third Party Claim using equitable remedies (i.e., remedies involving future
activity of the Indemnified Party), the Indemnifying Party and the Indemnified
Party shall work together in good faith to agree to a settlement; provided,
however, that no Party shall be under any obligation to agree to any such
settlement.
(c)    Treatment of Indemnification Payments; Insurance Recoveries. Any
indemnity payment under this Agreement shall be decreased by any amounts
actually recovered by the Indemnified Party under Third Party insurance policies
with respect to such Indemnified Losses (net of any premiums paid by such
Indemnified Party under the relevant insurance policy). Each Party agrees (i) to
use all reasonable efforts to recover all available insurance proceeds and (ii)
to the extent that any indemnity payment under this Agreement has been paid by
the Indemnifying Party to the Indemnified Party prior to the recovery by the
Indemnified Party of such insurance proceeds, the amount of such insurance
proceeds actually recovered by the Indemnified Party shall be promptly paid to
the Indemnifying Party.
(d)    Certain Additional Procedures. The Indemnified Party shall cooperate and
assist the Indemnifying Party in determining the validity of any Third Party
Claim and in otherwise resolving such matters. The Indemnified Party shall
cooperate in the defense by the Indemnifying Party of each Third Party Claim
(and the Indemnified Party and the Indemnifying Party agree with

DLI-266520155v1
35

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

respect to all such Third Party Claims that a common interest privilege
agreement exists between them), including: (i) permitting the Indemnifying Party
to discuss the Third Party Claim with such officers, employees, consultants and
representatives of the Indemnified Party as the Indemnifying Party reasonably
requests; (ii) providing to the Indemnifying Party copies of documents and
samples of products as the Indemnifying Party reasonably requests in connection
with defending such Third Party Claim; (iii) preserving all properties, books,
records, papers, documents, plans, drawings, electronic mail and databases of
the Indemnifying Party and relating to matters pertinent to the conduct of the
Indemnifying Party under the Indemnified Party’s custody or control in
accordance with such Party’s corporate documents retention policies, or longer
to the extent reasonably requested by the Indemnifying Party; (iv) notifying the
Indemnifying Party promptly of receipt by the Indemnified Party of any subpoena
or other Third Party request for documents or interviews and testimony; (v)
providing to the Indemnifying Party copies of any documents produced by the
Indemnified Party in response to or compliance with any subpoena or other Third
Party request for documents; and (vi) except to the extent inconsistent with the
Indemnified Party’s obligations under Applicable Law and except to the extent
that to do so would subject the Indemnified Party or its employees, agents or
representatives to criminal or civil sanctions, unless ordered by a court to do
otherwise, not producing documents to a Third Party until the Indemnifying Party
has been provided a reasonable opportunity to review, copy and assert privileges
covering such documents.
ARTICLE 10
LIMITATION OF LIABILITY
10.1    Damages Limitation. SUBJECT TO SECTION 10.2, IN NO EVENT SHALL ANY PARTY
BE LIABLE TO ANOTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR OTHER
INDIRECT DAMAGES OR ANY PUNITIVE OR EXEMPLARY DAMAGES ARISING OUT OF, OR IN
CONNECTION WITH, THIS AGREEMENT, WHETHER SUCH DAMAGES ARE BASED ON BREACH OF
CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, EVEN IF A
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
10.2    Exclusions. Section 10.1 shall not apply to Section 7.4(c) or to any
Party’s breach of Article 8.
10.3    Mitigation. Each Party shall have a duty to use commercially reasonable
efforts to mitigate damages for which another Party is responsible.

DLI-266520155v1
36

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ARTICLE 11
TERM AND TERMINATION
11.1    Term. The term of this Agreement (the “Term”) shall commence on the
Effective Date and continue in effect until, but not including, January 1, 2016,
whereupon this Agreement shall terminate.
11.2    Termination.
(a)    Except as otherwise provided in this Section 11.2, this Agreement may not
be terminated by any Party during the Term.
(b)    Notwithstanding anything herein to the contrary, upon the occurrence of
an [***] (as defined in the Joint Venture Agreement), if [***] (as defined in
the Joint Venture Agreement) within [***] (or such other period as the Purchaser
may agree in writing) following the [***], [***] and [***] shall have the right
to terminate this Agreement effective upon written notice to [***], provided
that [***].
(c)    Any [***] shall contemplate the [***] to ensure that Inotera has the
ability to [***] the Applicable [***] Target [***] (the “[***]”) by the
Applicable [***] Deadline. Notwithstanding anything herein to the contrary, if
at any time the [***] is not reflected in a [***] or it becomes reasonably
apparent that the [***] will not occur by the Applicable [***], Micron and the
Purchaser shall have the right, which they may exercise by written notice to
Inotera, to (A) terminate this Agreement or (B) terminate the Purchaser’s [***],
which right shall survive the termination of such obligation; provided, however,
that the right of Micron and the Purchaser under this Section 11.2(c) as it
relates to the [***] shall terminate if not exercised by written notice to
Inotera prior to the earlier of (x) the date that is [***] following the
occurrence of the Applicable [***] Deadline and (y) the date on which the [***]
occurs. Any written notice delivered by Micron and the Purchaser to Inotera
pursuant to this Section 11.2(c) shall specify whether Micron and the Purchaser
are exercising the termination right contemplated by clause (A) above or the
termination right contemplated by clause (B) above and when such termination
shall become effective.
(d)    Notwithstanding anything herein to the contrary, Micron and the Purchaser
shall have the right to terminate this Agreement, effective upon written notice
to Inotera, in the event that: (i) Inotera files a petition under or otherwise
seeks to take advantage of laws relating to bankruptcy, insolvency, suspension
of payments, reorganization or rehabilitation, or makes a general assignment for
the benefit of creditors, or otherwise acknowledges in writing insolvency, or is
declared or adjudicated bankrupt or insolvent; (ii) Inotera commences a process
of dissolution, liquidation or winding up; (iii) Inotera applies for or consents
to the appointment of a trustee, receiver, administrator, custodian, liquidator
or the like for itself or any substantial portion of its business or assets; or
(iv) Inotera or any substantial portion of its business or assets involuntarily
becomes the subject of any such filing, process or appointment and such
involuntary filing, process or appointment is not stayed, rescinded, removed or
otherwise eliminated within sixty (60) days.

DLI-266520155v1
37

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(e)    Notwithstanding anything herein to the contrary, this Agreement may be
terminated:
(i)    by Inotera, effective upon written notice to Micron and the Purchaser, if
there has been a material breach by Micron or the Purchaser of any material
covenant or agreement contained in this Agreement and such breach has not been
(A) cured by Micron or the Purchaser within thirty (30) days after written
notice thereof from Inotera or (B) waived by Inotera; or
(ii)    by Micron and the Purchaser, effective upon written notice to Inotera,
if there has been a material breach by Inotera of any material covenant or
agreement contained in this Agreement and such breach has not been (A) cured by
Inotera within thirty (30) days after written notice thereof from Micron and the
Purchaser or (B) waived by Micron and the Purchaser.
11.3    Inotera Requirements at Termination. Within [***] days after the
effectiveness of any termination of this Agreement pursuant to Section 11.2,
Inotera:
(a)    shall deliver to Micron, or, pursuant to written instructions of Micron,
destroy, all production masks obtained as contemplated by Section 2.3; and
(b)    shall (i) deliver to Micron, or, pursuant to written instructions of
Micron, destroy, all copies and other embodiments of any process technology or
information provided to Inotera by Micron or its Affiliates, or any portion
thereof, in whatever form received, reproduced or stored, (ii) if destruction is
requested by Micron, certify to Micron and the Purchaser that such destruction
is complete, and (iii) cease all use of the process technology or information
provided to Inotera by Micron or its Affiliates.
11.4    Survival. Termination of this Agreement shall not affect any of the
Parties’ respective rights accrued, or obligations owed, before such
termination. In addition, (a) the following shall survive termination of this
Agreement for any reason, insofar as they relate to DRAM Products delivered by
Inotera, or otherwise relate to the Parties’ respective performance of this
Agreement, prior to such termination: Sections 2.7, 3.11, 3.13, 4.2, 4.5, 4.8,
4.9, 4.11, 4.12, 4.13, 4.14, 6.4, 7.1, 7.2 and 7.5 and Articles 5, 9, 10 and 11
and (b) the following shall survive termination of this Agreement for any reason
without limitation: Section 3.16, 4.10 and 7.4(c) and Articles 8 and 12. For the
avoidance of doubt, the Parties acknowledge and agree that the pricing terms set
forth in the 2016 Supply Agreement, and not those set forth in this Agreement,
shall govern with respect to any wafers that are loaded by Inotera prior to
January 1, 2016 and delivered by Inotera to the Purchaser on or after January 1,
2016.

DLI-266520155v1
38

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ARTICLE 12
MISCELLANEOUS
12.1    Force Majeure Events. The Parties shall be excused from any failure to
perform any obligation hereunder to the extent such failure is caused by a Force
Majeure Event. A Force Majeure Event shall operate to excuse a failure to
perform an obligation hereunder only for the period of time during which the
Force Majeure Event renders performance impossible or infeasible and only if the
Party asserting Force Majeure as an excuse for its failure to perform has
provided written notice to, in the event of an assertion by Micron or the
Purchaser, Inotera and, in the event of an assertion by Inotera, Micron and the
Purchaser specifying the obligation to be excused and describing the events or
conditions constituting the Force Majeure Event.
12.2    Specific Performance. The Parties agree that irreparable damage will
result if this Agreement is not performed in accordance with its terms, and the
Parties agree that any damages available under the indemnification provisions or
at law for a breach of this Agreement would not be an adequate remedy.
Therefore, the provisions hereof and the obligations of the Parties hereunder
shall be enforceable in a court of equity, or other tribunal with jurisdiction,
by a decree of specific performance, and appropriate injunctive relief may be
applied for and granted in connection therewith.
12.3    Assignment. This Agreement shall be binding upon and inure to the
benefit of the successors and assigns of each Party hereto; provided, however,
neither this Agreement nor any right or obligation hereunder may be assigned or
delegated by any Party in whole or in part to any other Person without the prior
written consent of the nonassigning Parties. Any purported assignment in
violation of the provisions of this Section 12.3 shall be null and void and have
no effect.
12.4    Compliance with Laws and Regulations. Each of the Parties shall comply
with, and shall use reasonable efforts to require that its respective
subcontractors comply with, Applicable Laws relating to this Agreement and the
performance of such Party’s obligations hereunder.
12.5    Notice. All notices and other communications hereunder shall be in
writing and shall be deemed given upon (a) transmitter’s confirmation of a
receipt of a facsimile transmission, (b) confirmation of delivery by a standard
overnight or recognized international carrier, or (c) delivery in person,
addressed at the following addresses (or at such other address for a Party as
shall be specified by like notice):

DLI-266520155v1
39

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

In the case of Micron:

Micron Technology, Inc.
8000 S. Federal Way
Mail Stop 1-507
Boise, ID 83716
Attn: General Counsel
Facsimile: (208) 368-1309
In the case of the Purchaser:

Micron Semiconductor Asia Pte. Ltd.
c/o Micron Technology, Inc.
8000 S. Federal Way
Mail Stop 1-507
Boise, ID 83716
Attn: General Counsel
Facsimile: (208) 368-1309
In the case of Inotera:

Inotera Memories, Inc.
667, Fuhsing 3rd Road
Hwa-Ya Technology Park
Kueishan, Taoyuan
Taiwan, R.O.C.
Attn: Director of Legal & IP Office
Facsimile: 886-3-327-0037
12.6    Waiver. The failure at any time of a Party to require performance by
another Party of any responsibility or obligation required by this Agreement
shall in no way affect a Party’s right to require such performance at any time
thereafter, nor shall the waiver by a Party of a breach of any provision of this
Agreement by another Party constitute a waiver of any other breach of the same
or any other provision nor constitute a waiver of the responsibility or
obligation itself.
12.7    Severability. Should any provision of this Agreement be deemed in
contradiction with the laws of any jurisdiction in which it is to be performed
or unenforceable for any reason, such provision shall be deemed null and void,
but this Agreement shall remain in full force and effect in all other respects.
Should any provision of this Agreement be or become ineffective because of
changes in Applicable Laws or interpretations thereof, or should this Agreement
fail to include a provision that is required as a matter of law, the validity of
the other provisions of this Agreement shall not be affected thereby. If such
circumstances arise, the Parties shall negotiate in good faith appropriate
modifications to this Agreement to reflect those changes that are required by
Applicable Law.

DLI-266520155v1
40

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

12.8    Third Party Rights. Except as expressly provided in Article 9, nothing
in this Agreement, whether express or implied, is intended, or shall be
construed, to confer, directly or indirectly, upon or give to any Person, other
than the Parties hereto, any legal or equitable right, remedy or claim under or
in respect of this Agreement or any covenant, condition or other provision
contained herein.
12.9    Amendment. This Agreement may not be modified or amended except by a
written instrument executed by, or on behalf of, each of the Parties.
12.10    Entire Agreement. This Agreement, together with the agreements and
instruments expressly provided for herein (including the Micron/Inotera
Confidentiality Agreement), constitute the entire agreement of the Parties with
respect to the subject matter hereof and supersede all prior agreements and
understandings, oral and written, among the Parties with respect to the subject
matter hereof.
12.11    Choice of Law. This Agreement shall be governed by and construed in
accordance with the laws of the R.O.C., without giving effect to its conflict of
laws principles.
12.12    Jurisdiction; Venue. Any suit, action or proceeding seeking to enforce
any provision of, or based on any matter arising out of or in connection with,
this Agreement shall be brought in the Taipei District Court, located in Taipei,
Taiwan, and each of the Parties hereby consents and submits to the exclusive
jurisdiction of such court (and of the appropriate appellate courts therefrom)
in any such suit, action or proceeding and irrevocably waives, to the fullest
extent permitted by Applicable Law, any objection which it may now or hereafter
have to the laying of the venue of any such suit, action or proceeding in any
such court or that any such suit, action or proceeding which is brought in any
such court has been brought in an inconvenient forum.
12.13    Headings. The headings of the Articles and Sections in this Agreement
are provided for convenience of reference only and shall not be deemed to
constitute a part hereof.
12.14    Counterparts. This Agreement may be executed in several counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
12.15    Insurance. Without limiting or qualifying Inotera’s liabilities,
obligations or indemnities otherwise assumed by Inotera pursuant to this
Agreement, Inotera shall at all times (except as otherwise stipulated in
Schedule 12.15), for so long as this Agreement remains in effect (and
notwithstanding any termination of the Joint Venture Agreement), maintain in
effect insurance of the types and in the amounts set forth on Schedule 12.15 or
as otherwise agreed by the Parties from time to time. Such insurance coverage
may be provided through the coverage under one or more insurance policies
maintained by Micron, NTC or any of their respective Affiliates.

DLI-266520155v1
41

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

12.16    Micron Undertaking. Micron shall unconditionally cause the Purchaser to
perform its obligations under this Agreement and hereby unconditionally
guarantees the due performance of all such obligations by the Purchaser,
including the payment of any amounts owing by the Purchaser under this
Agreement. Such guarantee is an independent obligation of Micron and upon any
default by the Purchaser in the performance of its obligations, including the
payment of any amounts owing by the Purchaser, under this Agreement, Inotera may
immediately proceed against Micron without proceeding against the Purchaser or
joining the Purchaser.

[SIGNATURE PAGES FOLLOW]

DLI-266520155v1
42

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

IN WITNESS WHEREOF, this Agreement has been duly executed by, and on behalf of,
the Parties as of the Agreement Date.
 
MICRON TECHNOLOGY, INC.

 
By:
/s/ Michael Sadler
 
 
Name: Michael Sadler
 
 
Title: VP Corp. Development
 
 
 
 
 
 

THIS IS A SIGNATURE PAGE FOR THE
2015 SUPPLY AGREEMENT
ENTERED INTO BY AND AMONG
MICRON, THE PURCHASER AND INOTERA

DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

 
MICRON SEMICONDUCTOR ASIA PTE. LTD.

 
By:
/s/ Lee Kok Choy
 
 
Name: Lee Kok Choy
 
 
Title: Director

THIS IS A SIGNATURE PAGE FOR THE
2015 SUPPLY AGREEMENT
ENTERED INTO BY AND AMONG
MICRON, THE PURCHASER AND INOTERA

DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

 
INOTERA MEMORIES, INC.

 
By:
/s/ Chaun Lin
 
 
Name: Chaun Lin
 
 
Title: Independent Director
 
 
 

THIS IS A SIGNATURE PAGE FOR THE
2015 SUPPLY AGREEMENT
ENTERED INTO BY AND AMONG
MICRON, THE PURCHASER AND INOTERA

DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 1.1 – CERTAIN SPECIFICATIONS/QUALITY AND
RELIABILITY STANDARDS AND CONTROL AND PROCESS MECHANISMS

Quality Conforming Material Requirements

1)
All DRAM Products shall have a lifetime of [***] or more as determined by
reliability testing or a suitable proxy (“Reliability Testing”). Inotera shall
conduct such Reliability Testing, which shall include, but shall not be limited
to, Fast Wafer Level Reliability (“FWLR”) tests for CHC and CHISEL and standard
Slow Wafer Level Reliability (“SWLR”) tests for EM.

2)
In performing Reliability Testing, Inotera shall use specification limits and
engineering limits provided by Micron and three sigma control limits with
respect to measurement site level data, unless otherwise specified by Micron.

3)
Inotera shall conduct, and monitor the results of, Reliability Testing in a
manner consistent with the specification limits, engineering limits and control
limits referred to in item 2 above and with respect to each measurement site,
unless otherwise stated in Specifications. If such Reliability Testing shows a
failure of any such specification limit, engineering limit or control limit,
Inotera will comply with a reaction plan specified by Micron.

4)
If an OOS event occurs, Inotera shall follow the OSAP procedure specified by
Micron.

5)
If an OOC event occurs, Inotera shall follow the OCAP procedure specified by
Micron.

6)
Inotera shall run corner lots through Reliability Testing, including, if
applicable, any FWLR and SWLR tests, to develop, and test compliance with,
specifications reasonably acceptable to Micron for inline steps that can cause
degradation and will follow a disposition strategy reasonably acceptable to
Micron if such specifications are not met.

Schedule 1.1 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Final Probe Test Reliability Conformance Criteria
In testing reliability degradation mechanisms that can be tested via final probe
suite, Inotera shall conduct such tests and shall use the wafer level
specification limits listed in the table below. Inotera shall monitor the
results of probe testing around wafer level data, unless otherwise noted in
Specifications. Wafers exceeding such specification limits will be considered to
be Non-Conforming Wafers.
Wafer average cutoffs for [***] DRAM
(based on [***] Gb equivalent)

Final Test Register
Wafer Average Conformance Limit ([***] Gb equivalent)
rdV
[***]
rdB
[***]
rdE
[***]
rdD
[***]
rdt
[***]
rdT
[***]
rdC
[***]
rdf
[***]

Schedule 1.1 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 3.7 – [***]
The Parties agree that the “[***]” for a particular Delivery Month in which
[***] the Purchaser’s request that [***] in such Delivery Month [***] for such
Delivery Month set forth in the [***] delivered in the Fiscal Month prior to
such Delivery Month as contemplated by Section 3.7 shall be calculated in the
following manner:
“[***]” = A x (B – C)
where the components of such calculation have the meanings set forth below:
“I” = “Total Wafers” = includes Pre-Qual Engineering Wafers, Pre-Qual Production
Wafers, and Conforming Wafers,
“II” = “[***] Wafers” = includes [***]
“III” = “Wafers Subject To [***]” = I – II
“A” = “[***] Per Wafer” = D / B;
“B” = “[***]” = the sum of (a) the [***] for such Delivery Month, plus (b) the
[***] in such Delivery Month [***] that (i) the Purchaser requested [***] for
such Delivery Month set forth in the [***] delivered in the Fiscal Month prior
to such Delivery Month and that [***] were [***] for such Delivery Month and
(ii) the [***] for [***] was [***] for such Delivery Month;
“C” = “[***]” = the [***] in such Delivery Month;
“D” = “[***]” = the difference of (a) the quotient of (i) [***], excluding
[***], delivered to the Purchaser in the [***] of such Delivery Month,
calculated in accordance with [***], including an [***] in the [***] of such
Delivery Month [***] at the Purchaser’s request as contemplated by Section 3.7
(but excluding any [***]), divided by (ii) [***], minus (b) the [***] for such
Delivery Month;
“E” = “[***]” = the product of (a) the quotient of (i) [***] for such Delivery
Month, divided by (ii) [***] in such Delivery Month, multiplied by (b) the
quotient of (i) the [***] of such Delivery Month, divided by (ii) [***];
“F” = “[***]” = G + H + I + J;
“G” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***];
“H” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***];
“I” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***], an example of which is set forth on Attachment 1 to Schedule 3.8; and

Schedule 3.7 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“J” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***], an example of which is set forth on Attachment 1 to Schedule 3.8.
An example of the [***] calculation is set forth on Attachment 1 to this
Schedule 3.7. Notwithstanding anything to the contrary herein, the following
shall not be included in the calculation of [***] or [***]: (a) any [***]; (b)
any [***]; (c) any [***]; or (d) any [***] at the Purchaser’s request as
contemplated by Section 3.7.

Schedule 3.7 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 1
TO
SCHEDULE 3.7
EXAMPLE CALCULATIONS OF
[***]

Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 1 to Schedule 3.7
Example Calculation of [***]

 
 
I
II
III
 
 
Total Wafers
[***] Wafers
Wafers Subject to [***]
 
[***]*
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
G
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
H
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
I
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
J
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
F
Subtotal [***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
[***]
 
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
[***]
 
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
[***]
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
[***]
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C
[***]
 
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
[***]
 
[***]
 
 
 
 
 
 
 
[***]
 
 
B
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A=D/B
[***] per Wafer
 
 
 
 
 
 
 
 
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A*(B-C)
[***]
 
 
 
 
 
 
 
 
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

*
[***]

**
[***]

Attachment 1 to Schedule 3.7 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 3.8 - [***] AND [***]

1.    [***]. The Parties agree that the “[***]” for a particular Delivery Month
in which [***] manufactured utilizing [***] were delivered to the Purchaser, as
contemplated by Section 3.8, have been delivered to the Purchaser shall be [***]
calculated in the following manner:
“[***]” = (A – B) x C
where the components of such calculation have the meanings set forth below:
“I” = “Total Wafers” = includes Pre-Qual Engineering Wafers, Pre-Qual Production
Wafers, and Conforming Wafers,
“II” = “[***] Wafers” = includes [***].
“III” = “Wafers Subject To [***]” = I – II
“A” = “[***] Per Wafer” = (D + E + F + G) / H;
“B” = “[***] Per Wafer” = I / H;
“C” = “[***]” = the [***] in such Delivery Month;
“D” = “[***]” = [***] for such Delivery Month, calculated in accordance [***];
“E” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***];
“F” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***], an example of which is set forth on Attachment 1 to this Schedule 3.8;
“G” = “[***]” = [***] for such Delivery Month, calculated in accordance with
[***], an example of which is set forth on Attachment 1 to this Schedule 3.8;
“H” = “[***]” = the [***] in such Delivery Month; and
“I” = “[***]” = [***] in such Delivery Month, calculated in accordance with
[***].
An example of the [***] calculation is set forth on Attachment 2 to this
Schedule 3.8. Notwithstanding anything to the contrary herein, the following
shall not be included in the calculation of [***]: (a) any [***]; (b) any [***];
(c) any [***]; or (d) any [***].

Schedule 3.8 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

2.    [***]. The Parties agree that the “[***]” for a particular Process Node
for a particular Delivery Month shall be [***] calculated in the following
manner:
“[***]” = (A – B) / 2
where the components of such calculation have the meanings set forth below:
“I” = “Total Wafers” = includes Pre-Qual Engineering Wafers, Pre-Qual Production
Wafers, and Conforming Wafers,
“II” = “[***] Wafers” = includes [***].
“III” = “Wafers Subject To [***]” = I – II“A” = “[***]” = [***] in such Delivery
Month, calculated in accordance with [***]; provided, however, that, if [***] is
no longer being utilized to manufacture Conforming Wafers and Pre-Qual
Production Wafers, then [***] shall be disregarded; and
“B” = “[***]” = the difference of (a) [***] in such Delivery Month, minus (b)
the [***] in such Delivery Month, in each case calculated in accordance with
[***]; provided, however, that, if [***] is no longer being utilized to
manufacture wafers, then [***] shall be disregarded in both clauses (a) and (b)
above.”
An example of the [***] calculation is set forth on Attachment 3 to this
Schedule 3.8. Notwithstanding anything to the contrary herein, the following
shall not be included in the calculation of [***]: (a) any [***] or [***]; (b)
any [***]; (c) any [***]; or (d) any [***].

Schedule 3.8 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 1
TO
SCHEDULE 3.8
EXAMPLE CALCULATIONS OF
[***] AND [***]
See attached.

Attachment 1 to Schedule 3.8 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

[inotera.jpg]

Attachment 1 to Schedule 3.8 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

[inoterab.jpg]

Attachment 1 to Schedule 3.8 – Page 3
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

New Methodology for
[***] per Wafer Calculation

--------------------------------------------------------------------------------

n
Starting Month and Result

1.
[***]

2.
[***]

[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
 
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
 
 
 
 
 
 
 
[***]
[***]
[***]
 
 
 
[***]
[***]
[***]
[***]
 
 
 
[***]
[***]
[***]
[***]
 
 
 
[***]
[***]
[***]
[***]
 
 
 
[***]
[***]
[***]
[***]
 
 
[***]
[***]
[***]
[***]
 
 
 
[***]

--------------------------------------------------------------------------------

Confidential    Page 5 of 8    IMI AFC
        07/06/2009

Attachment 1 to Schedule 3.8 – Page 4
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

[inoterac.jpg]

Attachment 1 to Schedule 3.8 – Page 5
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 2
TO
SCHEDULE 3.8
EXAMPLE CALCULATIONS OF
[***]

Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 1 to Schedule 3.8
Example Calculation of [***]

 
 
I
II
III
 
 
Total Wafers
[***] Wafers
Wafers Subject to [***]
C
[***]
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
E
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
F
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
G
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
Subtotal [***]*
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A=(D+E+F+G)/H
[***] per Wafer
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B=I/H
[***] per Wafer
 
 
 
 
 
 
 
 
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A-B)*C
[***]
 
 
 
 
 
 
 
 
 
 
$
[***]

*
[***]

Attachment 2 to Schedule 3.8 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 3
TO
SCHEDULE 3.8
EXAMPLE CALCULATIONS OF
[***]

Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 2 to Schedule 3.8
Example Calculation of [***]

 
 
I
II
III
 
 
Total Wafers
[***] Wafers
Wafers Subject to [***]
A
[***]
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
[***]
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
B
[***]
 
 
$
[***]
 
 
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A-B)/2
[***]
 
 
$
[***]
 
 
$
[***]
 
[***]
$
[***]

*
[***]

Attachment 3 to Schedule 3.8 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 3.13 – [***] PAYMENT AMOUNTS
1.    [***] Payment Amount. The Parties agree that the “[***] Payment Amount”
for any Delivery Month shall be calculated in the following manner:
“[***] Payment Amount” = [***]
where the components of such calculation, and the related terms, have the
meanings set forth below. An example of the [***] Payment Amount calculation is
set forth on Attachment 1 to this Schedule 3.13. Each accounting term used in
this Schedule 3.13 shall be applied in accordance with GAAP or, if such term is
not a GAAP accounting term, in accordance with Micron’s general accounting
policies.
“A” = “[***] Revenue” = Micron’s net revenue in the Secondary Die Measurement
Period associated with the sale [***] of Non-HMC DRAM Products (whether sold in
die, wafer, packaged, module or subsequent form, but excluding DRAM Products
contained on Multi-Chip Products) produced from Secondary Die manufactured by
Inotera, determined on a particular Design ID basis;
“B” = “[***]” = the [***] for such Delivery Month;
“C” = “[***] BEOL Costs” = the back end [***] costs incurred on a particular
Design ID in the [***] Measurement Period by Micron and its consolidated
Affiliates to produce Non-HMC DRAM Products in packaged, module or subsequent
form (but not Multi-Chip Products) [***], including (a) [***] back end [***] and
(b) [***] back end [***]; and
“D” = “[***]” = [***].
2.    Related Definitions.
“[***]” means, for a particular Design ID, any die of such Design ID that [***]
such die [***].
“[***] Measurement Period” means, for a particular Delivery Month, [***].

Schedule 3.13 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 1
TO
SCHEDULE 3.13
EXAMPLE CALCULATIONS OF
[***] PAYMENT AMOUNTS
Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 1 to Schedule 3.13
Example Calculation of [***] Payment Amounts

A
[***] Revenue
$
[***]
B
[***]
 
[***]
 
 
 
 
C
[***] BEOL Costs
$
[***]
D
[***]
 
[***]
 
 
 
 
[***]
[***] Payment Amount
$
[***]
 
 
 
 

Attachment 1 to Schedule 3.13 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 5.1 - PRICE OF NON-HMC CONFORMING WAFERS AND NON-HMC PRE-QUAL
PRODUCTION WAFERS
The Parties agree that the “Price” of each Non-HMC Conforming Wafer of a
particular Design ID for any Delivery Month and the “Price” of each Non-HMC
Pre-Qual Production Wafer of a particular Design ID for any Delivery Month shall
be calculated in the following manner.
“Price” of each Non-HMC Conforming Wafer = Baseline Price Per Wafer [***]; and
“Price” of each Non-HMC Pre-Qual Production Wafer = Baseline Price Per Wafer
where the components of such calculation, and the related terms, have the
meanings set forth below. An example of the Price calculation is set forth on
Attachment 1 to this Schedule 5.1. Each accounting term used in this Schedule
5.1 shall be applied in accordance with GAAP or, if such term is not a GAAP
accounting term, in accordance with Micron’s general accounting policies.
1.    Baseline Price Per Wafer. Baseline Price Per Wafer for any Delivery Month
is (a) calculated as set forth below for each Process Node utilized by Inotera
to manufacture Non-HMC Conforming Wafers and Non-HMC Pre-Qual Production Wafers
for delivery to the Purchaser in such Delivery Month and (b) used in the
calculation of the Price in such Delivery Month of Non-HMC Conforming Wafers and
Non-HMC Pre-Qual Production Wafers of each Design ID manufactured using such
Process Node.
“Baseline Price Per Wafer” = (Adjusted Worldwide Revenue Per Node / Worldwide
[***] Wafers [***] Per Node) – (Adjusted Worldwide BEOL Costs Per Node /
Worldwide [***] Wafers [***] Per Node), where
“Adjusted Worldwide Revenue Per Node” = ((A x (1 - C)) + (B x (1 - C - D))) x (1
+ I)
“Adjusted Worldwide BEOL Costs Per Node” = E x F
“Worldwide [***] Wafers [***] Per Node” = G
“Worldwide [***] Wafers [***] Per Node” = H
where the components of such calculation have the meanings set forth below:
“A” = “Worldwide DRAM Revenue Per Node” = Micron’s net revenue in the
Measurement Period associated with the sale [***] of Non-HMC DRAM Products
(whether sold in die, wafer, packaged, module or subsequent form, but excluding
Non-HMC DRAM Products contained on Multi-Chip Products) produced from Prime Die
manufactured using such Process Node, determined on a consolidated basis;

Schedule 5.1 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“B” = “[***] Worldwide Multi-Chip Revenue Per Node” = B1 - B2;
“B1” = “Worldwide Multi-Chip Revenue Per Node” = Micron’s net revenue in the
Measurement Period associated with the sale [***] of Multi-Chip Products that
contain Non-HMC DRAM Products produced from Prime Die manufactured using such
Process Node, determined on a consolidated basis,
“B2” = “[***] Worldwide Multi-Chip Revenue Per Node” = the sum of the following
for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced
from Prime Die manufactured using such Process Node: the product of (a) the
quotient of (i) the difference of (A) Micron’s net revenue in the Measurement
Period associated with the sale [***] of [***] (whether sold in die, wafer,
packaged, module or subsequent form, but excluding [***] Multi-Chip Products)
produced from prime die [***], determined on a consolidated basis, minus (B) the
aggregate back end [***] costs incurred in the Measurement Period by Micron and
its consolidated Affiliates [***], including (I) [***] back end [***] and (II)
[***] back end [***], divided by (ii) the number of prime die [***] Micron and
its consolidated Affiliates [***] in the Measurement Period (but excluding [***]
Multi-Chip Products), multiplied by (b) the number of prime die [***] on such
Multi-Chip Products [***] Micron and its consolidated Affiliates during the
Measurement Period;
“C” = “Applicable DRAM Discount” = the Applicable DRAM Discount for such
Delivery Month as set forth in Section 4 of this Schedule 5.1;
“D” = “[***]” = [***], unless, for a particular Process Node, the [***] is [***]
for such Process Node, then [***];
“E” = “Worldwide DRAM BEOL Costs Per Node” = the aggregate back end [***] costs
incurred in the Measurement Period by Micron and its consolidated Affiliates to
produce Non-HMC DRAM Products and Multi-Chip Products that contain such Non-HMC
DRAM Products in packaged, module or subsequent form using the Prime Die
manufactured using such Process Node, including (a) [***] back end [***] and (b)
[***] back end [***];
“F” = “[***]” = [***];
“G” = “Worldwide [***] Wafers [***] Per Node” = the sum of the following for
each Design ID manufactured using such Process Node: the quotient of (a) the
number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products
and Multi-Chip Products [***] Micron and its consolidated Affiliates in the
Measurement Period, divided by (b) the average number of Prime Die per wafer of
such Design ID manufactured [***] Micron and its consolidated Affiliates in the
Measurement Period, [***], divided by (c) [***] for such Non-HMC DRAM Products
in the Measurement Period;
“G1” = “[***]” = 1 – (G2 / (G2 + G3 + G4));

Schedule 5.1 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“G2” = “[***]” = the sum of (a) the difference of (i) the aggregate number of
Prime Die of such Design ID [***] of Non-HMC DRAM Products of such Design ID for
Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii)
the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products
of such Design ID for Micron and its consolidated Affiliates [***] the
Measurement Period, minus (iii) the aggregate number of Prime Die of such Design
ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates during the Measurement Period plus (b) [***] during the Measurement
Period, plus (c) [***] during the Measurement Period;
“G3” = “[***]” = the aggregate number of Prime Die of such Design ID contained
in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent
form, excluding Prime Die of such Design ID contained on Multi-Chip Products)
[***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of
such Design ID for Micron and its consolidated Affiliates during the Measurement
Period;
“G4” = “[***]” = the aggregate number of Prime Die of such Design ID [***]
Multi-Chip Products during the Measurement Period;
“H” = “Worldwide [***] Wafers [***] Per Node” = the sum of the following for
each Design ID manufactured using such Process Node: the quotient of (a) the sum
of (i) the aggregate number of Prime Die of such Design ID contained in Non-HMC
DRAM Products (whether in die, wafer, packaged, module or subsequent form,
excluding Prime Die of such Design ID contained on Multi-Chip Products) [***]
Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of such
Design ID for Micron and its consolidated Affiliates during the Measurement
Period, plus (ii) the aggregate number of Prime Die of such Design ID contained
on Multi-Chip Products [***] for Micron and its consolidated Affiliates during
the Measurement Period, divided by (b) the average number of Prime Die per wafer
of such Design ID manufactured [***] Micron and its consolidated Affiliates in
the Measurement Period, [***] [***] divided by (c) [***] for such Non-HMC DRAM
Products in the Measurement Period;
“I” = “Worldwide Revenue [***] Factor Per Node” = ((J / G) – (K / N)) / (K / N);
“J” = “Worldwide Revenue Per Node” = A + B;
“K” = “[***] Worldwide Revenue Per Node” = L + M;
“L” = “[***] Worldwide DRAM Revenue Per Node” = Micron’s net revenue [***]
associated with the sale [***] of Non-HMC DRAM Products (whether sold in die,
wafer, packaged, module or subsequent form, but excluding Non-HMC DRAM Products
contained on Multi-Chip Products) produced from Prime Die manufactured using
such Process Node, determined on a consolidated basis;
“M” = “[***] Worldwide Multi-Chip Revenue Per Node” = M1 - M2;

Schedule 5.1 – Page 3
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“M1” = “[***] Worldwide Multi-Chip Revenue Per Node” = Micron’s net revenue in
the Measurement Period associated with the sale [***] of Multi-Chip Products
that contain Non-HMC DRAM Products produced from Prime Die manufactured using
such Process Node, determined on a consolidated basis,
“M2” = “[***] Worldwide Multi-Chip Revenue Per Node” = the sum of the following
for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced
from Prime Die manufactured using such Process Node: the product of (a) the
quotient of (i) the difference of (A) Micron’s net revenue [***] associated with
the sale [***] of [***] (whether sold in die, wafer, packaged, module or
subsequent form, but excluding [***] Multi-Chip Products) produced from prime
die [***], determined on a consolidated basis minus (B) the aggregate back end
[***] costs incurred [***], including (I) [***] back end [***] and (II) [***]
back end [***], divided by (ii) the number of prime die [***] Micron and its
consolidated Affiliates [***] (but excluding [***] Multi-Chip Products),
multiplied by (b) the number of prime die [***] on such Multi-Chip Products
[***] Micron and its consolidated Affiliates [***];
“N” = “[***] Worldwide [***] Wafers [***] Per Node” = the sum of the following
for each Design ID manufactured using such Process Node: the quotient of (a) the
number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products
and Multi-Chip Products [***] Micron and its consolidated Affiliates [***],
divided by (b) the average number of Prime Die per wafer of such Design ID
manufactured [***] Micron and its consolidated Affiliates [***], divided by (c)
[***] for such Non-HMC DRAM Products [***];
“N1” = “[***]” = 1 – (N2 / (N2 + N3 + N4));
“N2” = “[***]” = the sum of (a) the difference of (i) the aggregate number of
Prime Die of such Design ID [***] for Micron and its consolidated Affiliates
[***], minus (ii) the aggregate number of Prime Die of such Design ID [***]
Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates [***], minus (iii) the aggregate number of Prime Die of such Design
ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates [***] plus (b) [***], plus (c) [***];
“N3” = “[***]” = the aggregate number of Prime Die of such Design ID contained
in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent
form, excluding Prime Die of such Design ID contained on Multi-Chip Products)
[***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of
such Design ID for Micron and its consolidated Affiliates [***]; and
“N4” = “[***]” = the aggregate number of Prime Die of such Design ID [***]
Multi-Chip Products [***].
2.    [***] Per Wafer. [***] Per Wafer for any Delivery Month is calculated for
each Design ID as described below; provided, however, that the [***] Per Wafer
will be [***] for a particular Design ID for a particular Delivery Month if
either (i) the Inotera Average [***] Wafers Probed for such

Schedule 5.1 – Page 4
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Design ID for such Delivery Month is [***], (ii) the Micron Average [***] Wafers
Probed for such Design ID for such Delivery Month is [***], or (iii) the Inotera
Average [***] Wafers Probed for such Design ID for such Delivery Month is [***]
for such Design ID for such Delivery Month.
“[***] Per Wafer” = [***] Per Wafer – [***] Per Wafer, where
“[***] Per Wafer” = ((Adjusted Worldwide Revenue Per Design ID / Worldwide Die
[***] Per Design ID) – (Adjusted Worldwide BEOL Costs Per Design ID / Worldwide
Die [***] Per Design ID)) x [***] Prime Die Per [***] Wafer [***]
“[***] Per Wafer” = ((Adjusted Worldwide Revenue Per Design ID / Worldwide Die
[***] Per Design ID) – (Adjusted Worldwide BEOL Costs Per Design ID / Worldwide
Die [***] Per Design ID) x [***] Prime Die Per [***] Wafer [***]
“Adjusted Worldwide Revenue Per Design ID” = ((A x (1 - C)) + (B x (1 - C - D)))
x (1 + M)
“Adjusted Worldwide BEOL Costs Per Design ID” = E x F
“Worldwide Die [***] Per Design ID” = I
“Worldwide Die [***] Per Design ID” = J
“[***] Prime Die Per [***] Wafer [***]” = K x G
“[***] Prime Die Per [***] Wafer [***]” = L x H
where the components of such calculation have the meanings set forth below.
“A” = “Worldwide DRAM Revenue Per Design ID” = Micron’s net revenue in the
Measurement Period associated with the sale [***] of Non-HMC DRAM Products
(whether sold in die, wafer, packaged, module or subsequent form, but excluding
Non-HMC DRAM Products contained on Multi-Chip Products) produced from Prime Die
of such Design ID, determined on a consolidated basis;
“B” = “[***] Worldwide Multi-Chip Revenue Per Design ID” = B1 - B2;
“B1” = “Worldwide Multi-Chip Revenue Per Design ID” = Micron’s net revenue in
the Measurement Period associated with the sale [***] of Multi-Chip Products
that contain Non-HMC DRAM Products produced from Prime Die of such Design ID,
determined on a consolidated basis,
“B2” = “[***] Worldwide Multi-Chip Revenue Per Design ID” = the sum of the
following for each [***] Multi-Chip Products that contain Non-HMC DRAM Products
produced from Prime Die of such Design ID: the product of (a) the quotient of
(i) the difference of (A) Micron’s net revenue in the Measurement Period
associated with the sale [***] of [***] (whether sold in die,

Schedule 5.1 – Page 5
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

wafer, packaged, module or subsequent form, but excluding [***] Multi-Chip
Products) produced from prime die [***], determined on a consolidated basis
minus (B) the aggregate back end [***] costs incurred in the Measurement Period
by Micron and its consolidated Affiliates [***], including (I) [***] back end
[***] and (II) [***] back end [***], divided by (ii) the number of prime die
[***] Micron and its consolidated Affiliates [***] in the Measurement Period
(but excluding [***] Multi-Chip Products), multiplied by (b) the number of prime
die [***] on such Multi-Chip Products [***] Micron and its consolidated
Affiliates during the Measurement Period;
“C” = “Applicable DRAM Discount” = the Applicable DRAM Discount for such
Delivery Month as set forth in Section 4 of this Schedule 5.1;
“D” = “[***]” = [***], unless, for a particular Process Node, the [***] is
[***], then [***];
“E” = “Worldwide DRAM BEOL Costs Per Design ID” = the aggregate back end [***]
costs incurred in the Measurement Period by Micron and its consolidated
Affiliates to produce Non-HMC DRAM Products and Multi-Chip Products that contain
such Non-HMC DRAM Products in packaged, module or subsequent form using the
Prime Die of such Design ID, including (a) [***] back end [***] and (b) [***]
back end [***];
“F” = “[***]” = [***];
“G” = “[***]” = 1 – (G1 / (G1 + G2 + G3));
“G1” = “[***]” = the sum of (a) the difference of (i) the aggregate number of
Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for
Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii)
the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products
of such Design ID for Micron and its consolidated Affiliates [***] the
Measurement Period, minus (iii) the aggregate number of Prime Die of such Design
ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates during the Measurement Period, plus (b) [***] during the Measurement
Period, plus (c) [***] during the Measurement Period;
“G2 = “[***]” = the aggregate number of Prime Die of such Design ID [***]
contained in Non-HMC DRAM Products (whether in die, wafer, packaged, module or
subsequent form, excluding Prime Die of such Design ID [***] contained on
Multi-Chip Products) [***] Non-HMC DRAM Products of such Design ID [***] Non-HMC
DRAM Products of such Design ID for Micron and its consolidated Affiliates
during the Measurement Period;
“G3” = “[***]” = the aggregate number of Prime Die of such Design ID [***]
Multi-Chip Products during the Measurement Period;

Schedule 5.1 – Page 6
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“H” = “[***]” = 1 – (H1 / (H1 + H2 + H3));
“H1” = “[***]” = the sum of (a) the difference of (i) the aggregate number of
Prime Die of such Design ID [***] Non-HMC DRAM Products of such Design ID for
Micron and its consolidated Affiliates [***] the Measurement Period, minus (ii)
the aggregate number of Prime Die of such Design ID [***] Non-HMC DRAM Products
of such Design ID for Micron and its consolidated Affiliates [***] the
Measurement Period, minus (iii) the aggregate number of Prime Die of such Design
ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates during the Measurement Period plus (b) [***] during the Measurement
Period, plus (c) [***] during the Measurement Period;
“H2” = “[***]” = the aggregate number of Prime Die of such Design ID contained
in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent
form, excluding Prime Die of such Design ID contained on Multi-Chip Products)
[***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of
such Design ID for Micron and its consolidated Affiliates during the Measurement
Period;
“H3” = “[***]” = the aggregate number of Prime Die of such Design ID [***]
Multi-Chip Products during the Measurement Period;
“I” = “Worldwide Die [***] Per Design ID” = the number of Prime Die of such
Design ID contained in or on Non-HMC DRAM Products and Multi-Chip Products [***]
Micron and its consolidated Affiliates [***] in the Measurement Period;
“J” = “Worldwide Die [***] Per Design ID” = the sum of (i) the aggregate number
of Prime Die of such Design ID contained in Non-HMC DRAM Products (whether in
die, wafer, packaged, module or subsequent form, excluding Prime Die of such
Design ID contained on Multi-Chip Products) [***] Non-HMC DRAM Products of such
Design ID [***] Non-HMC DRAM Products of such Design ID for Micron and its
consolidated Affiliates during the Measurement Period, plus (ii) the aggregate
number of Prime Die of such Design ID contained on Multi-Chip Products [***] for
Micron and its consolidated Affiliates during the Measurement Period;
“K” = “[***] Average Prime Die Per [***] Wafer” = the average number of Prime
Die per Non-HMC Conforming Wafer of such Design ID [***] the Purchaser in the
Measurement Period [***], [***];
“L” = “[***] Average Prime Die Per [***] Wafer” = the average number of Prime
Die per wafer of such Design ID [***] Micron and its consolidated Affiliates in
the Measurement Period, [***];
“M” = “Worldwide Revenue [***] Factor Per Node” = ((N / T) – (Q / U)) / (Q / U);
“N” = “Worldwide Revenue Per Node” = O + P;

Schedule 5.1 – Page 7
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

“O” = “Worldwide DRAM Revenue Per Node” = Micron’s net revenue in the
Measurement Period associated with the sale [***] of Non-HMC DRAM Products
(whether sold in die, wafer, packaged, module or subsequent form, but excluding
Non-HMC DRAM Products contained on Multi-Chip Products) produced from Prime Die
manufactured using such Process Node, determined on a consolidated basis;
“P” = “[***] Worldwide Multi-Chip Revenue Per Node” = P1 – P2;
“P1” = “Worldwide Multi-Chip Revenue Per Node” = Micron’s net revenue in the
Measurement Period associated with the sale [***] of Multi-Chip Products that
contain Non-HMC DRAM Products produced from Prime Die manufactured using such
Process Node, determined on a consolidated basis,
“P2” = “[***] Worldwide Multi-Chip Revenue Per Node” = the sum of the following
for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced
from Prime Die manufactured using such Process Node: the product of (a) the
quotient of (i) the difference of (A) Micron’s net revenue in the Measurement
Period associated with the sale [***] of [***] (whether sold in die, wafer,
packaged, module or subsequent form, but excluding [***] Multi-Chip Products)
produced from prime die [***], determined on a consolidated basis, minus (B) the
aggregate back end [***] costs incurred in the Measurement Period by Micron and
its consolidated Affiliates [***], including (I) [***] back end [***] or [***]
and (II) [***] back end [***], divided by (ii) the number of prime die [***]
Micron and its consolidated Affiliates [***] in the Measurement Period (but
excluding [***] Multi-Chip Products), multiplied by (b) the number of prime die
[***] on such Multi-Chip Products [***] Micron and its consolidated Affiliates
during the Measurement Period;
“Q” = “[***] Worldwide Revenue Per Node” = R + S;
“R” = “[***] Worldwide [***] Revenue Per Node” = Micron’s net revenue [***]
associated with the sale [***] of Non-HMC DRAM Products (whether sold in die,
wafer, packaged, module or subsequent form, but excluding Non-HMC DRAM Products
contained on Multi-Chip Products) produced from Prime Die manufactured using
such Process Node, determined on a consolidated basis;
“S” = “[***] Worldwide Multi-Chip Revenue Per Node” = S1 - S2;
“S1” = “[***] Worldwide Multi-Chip Revenue Per Node” = Micron’s net revenue in
the Measurement Period associated with the sale [***] of Multi-Chip Products
that contain Non-HMC DRAM Products produced from Prime Die manufactured using
such Process Node, determined on a consolidated basis,
“S2” = “[***] Worldwide Multi-Chip Revenue Per Node” = the sum of the following
for each [***] Multi-Chip Products that contain Non-HMC DRAM Products produced
from Prime Die manufactured using such Process Node: the product of (a) the
quotient of (i) the difference of (A) Micron’s net revenue [***] associated with
the sale [***] of [***] (whether sold in die, wafer,

Schedule 5.1 – Page 8
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

packaged, module or subsequent form, but excluding [***] Multi-Chip Products)
produced from prime die [***], determined on a consolidated basis minus (B) the
aggregate back end [***] costs incurred [***] by Micron and its consolidated
Affiliates [***], including (I) [***] back end [***] and (II) [***] back end
[***], divided by (ii) the number of prime die [***] Micron and its consolidated
Affiliates [***] (but excluding [***] Multi-Chip Products), multiplied by (b)
the number of prime die [***] on such Multi-Chip Products [***] Micron and its
consolidated Affiliates [***];
“T” = “Worldwide [***] Wafers [***] Per Node” = the sum of the following for
each Design ID manufactured using such Process Node: the quotient of (a) the
number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products
and Multi-Chip Products [***] Micron and its consolidated Affiliates in the
Measurement Period, divided by (b) the average number of Prime Die per wafer of
such Design ID manufactured [***] Micron and its consolidated Affiliates in the
Measurement Period, [***], divided by (c) [***] for such Non-HMC DRAM Products
in the Measurement Period;
“U” = “[***] Worldwide [***] Wafers [***] Per Node” = the sum of the following
for each Design ID manufactured using such Process Node: the quotient of (a) the
number of Prime Die of such Design ID contained in or on Non-HMC DRAM Products
and Multi-Chip Products [***] Micron and its consolidated Affiliates [***],
divided by (b) the average number of Prime Die per wafer of such Design ID
manufactured [***] Micron and its consolidated Affiliates [***], divided by (c)
[***] for such Non-HMC DRAM Products [***];
“U1” = “[***]” = 1 – (U2 / (U2 + U3 + U4));
“U2” = “[***]” = the sum of (a) the difference of (i) the aggregate number of
Prime Die of such Design ID [***] for Micron and its consolidated Affiliates
[***], minus (ii) the aggregate number of Prime Die of such Design ID [***]
Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates [***], minus (iii) the aggregate number of Prime Die of such Design
ID [***] Non-HMC DRAM Products of such Design ID for Micron and its consolidated
Affiliates [***] plus (b) [***], plus (c) [***];
“U3” = “[***]” = the aggregate number of Prime Die of such Design ID contained
in Non-HMC DRAM Products (whether in die, wafer, packaged, module or subsequent
form, excluding Prime Die of such Design ID contained on Multi-Chip Products)
[***] Non-HMC DRAM Products of such Design ID [***] Non-HMC DRAM Products of
such Design ID for Micron and its consolidated Affiliates [***]; and
“U4” = “[***]” = the aggregate number of Prime Die of such Design ID [***]
Multi-Chip Products [***].

Schedule 5.1 – Page 9
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

3.    Related Definitions.
“Inotera Average [***] Wafers Probed” means, with respect to a particular Design
ID for a particular Delivery Month, an amount equal to the quotient of (a) the
number of Non-HMC Conforming Wafers[***] of such Design ID delivered to the
Purchaser by Inotera that are subjected to Probe Testing [***], divided by (b)
the [***].
“Measurement Period” means, for a particular Delivery Month, the three most
recently completed fiscal months of the Purchaser including such Delivery Month.
“Micron Average [***] Wafers Probed” means, with respect to a particular Design
ID for a particular Delivery Month, an amount equal to the quotient of (a) the
number of conforming wafers[***] containing Non-HMC DRAM Products of such Design
ID manufactured by or for Micron and its Affiliates [***] that are subjected to
probe testing [***], divided by (b) the [***].
“Micron Fab Network Average [***] Wafers Probed” means, with respect to a
particular Design ID for a particular Delivery Month, an amount equal to the
quotient of (a) the number of conforming wafers [***] containing Non-HMC DRAM
Products of such Design ID manufactured [***] Micron and its Affiliates that are
subjected to probe testing [***], divided by (b) the [***].
“Multi-Chip Product” means [***].
“[***]” means [***].
“[***]” means [***].
“[***]” means [***].
“Prime Die” means, for a particular Design ID, a die that meets the applicable
Specifications for such Design ID immediately after Probe Testing and
immediately after final back-end testing.
“[***]” means, for a particular Delivery Month, [***].

Schedule 5.1 – Page 10
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

4.    Applicable DRAM Discount. The “Applicable DRAM Discount” for each Delivery
Month shall be as follows:
 
Applicable DRAM Discount
 
 
Unless Inotera’s EBITDA (as defined below) for [***] was:
[***]%
•    $[***] or higher
[***]%
•    between $[***] and $[***]
[***]%
•    between $[***] and $[***]
[***]%
•    between $[***] and $[***]
[***]%
•    between [***] $[***] and [***] $[***]
[***]%
•    less than [***] $[***]
[***]%

“EBITDA” means, for any particular [***], the sum of (a) the consolidated net
income of Inotera and its subsidiaries for such [***], plus, without duplication
and only to the extent deducted in calculating consolidated net income, (b) the
sum of (i) total interest expense for such [***], plus (ii) the aggregate
federal, state, local and foreign income taxes accrued or paid in cash during
such [***], plus (iii) the amount of depreciation and amortization expense for
such [***], plus (iv) any [***] for such [***], plus (v) any [***] for such
[***], minus, without duplication and only to the extent included in calculating
consolidated net income (c) the sum of (i) any [***] for such [***], plus (ii)
any [***] for such [***].
5.    Adjustments to Price Calculation.
(a)    Use of Proxy for First [***] of a New Non-HMC DRAM Product. In connection
with the calculation of the Price of a Non-HMC Conforming Wafer and Non HMC
Pre-Qual Production Wafer of a particular Design ID for a particular Delivery
Month, if any Non-HMC DRAM Product of a particular Design ID affecting such
calculation has not generated revenue (in the case of Non-HMC DRAM Products) for
all or a portion of the [***] immediately preceding Delivery Months, then the
Parties shall work together in good faith to determine the adjustments, based on
the use of the best available proxy consistent with historical practices of the
Parties, as are necessary or appropriate to accomplish the intent and purpose of
the inclusion of the “Measurement Period” and “[***]” concepts in this Schedule
5.1.

Schedule 5.1 – Page 11
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

(b)    Grace Period for First Non-HMC DRAM Product on a New Process Node. With
respect to the first Design ID of Non-HMC DRAM Product to be manufactured on a
newly installed Process Node at the Inotera Fab, the Price of Non-HMC Conforming
Wafers and Non HMC Pre-Qual Production Wafers of such Design ID for the first
[***] after qualification of such Design ID shall be the Baseline Price Per
Wafer for such Design ID, and the [***] for such [***] period shall be
disregarded and deemed not to exist in calculating Price of Non-HMC Conforming
Wafers and Non HMC Pre-Qual Production Wafers of such Design ID after such [***]
period.
(c)    Use of Proxy Where Data Not Available for [***]. In connection with the
calculation of the Price of a Non-HMC Conforming Wafer and Non HMC Pre-Qual
Production Wafer of a particular Design ID for a particular Delivery Month, if
any [***] affecting such calculation has not generated revenue for all or a
portion of the [***] immediately preceding Delivery Months, then the Parties
shall work together in good faith to determine the adjustments, based on the use
of the best available proxy, as are necessary or appropriate to accomplish the
intent and purpose of the calculation of [***] Worldwide Multi-Chip Revenue Per
Node, [***] Worldwide Multi-Chip Revenue Per Node, [***] Worldwide Multi-Chip
Revenue Per Design ID [***] and [***] Worldwide Multi-Chip Revenue Per Design ID
[***] in this Schedule 5.1.
(d)    Adjustment for [***] of Non-HMC DRAM Products. Notwithstanding anything
herein to the contrary, if (i) Micron and its consolidated Affiliates are unable
to sell into any particular premium market a proportion of the Non-HMC DRAM
Products contained on Non-HMC Conforming Wafers delivered to the Purchaser by
Inotera under this Agreement at least equal to the proportion of Non-HMC DRAM
Products contained on wafers manufactured by or for Micron and its consolidated
Affiliates at other fabs in the Micron Fab Network that are sold into such
premium market, and (ii) Inotera is [***], then sales into such premium market
by Micron and its consolidated Affiliates will be excluded from the calculation
of Price of Non-HMC Conforming Wafers, including the net revenue associated
therewith, the number of Prime Die of such Non-HMC DRAM Products sold and a
proportionate share of the back end [***] costs associated therewith [***].
(e)    If by [***] the Parties have not reached an agreement with respect to
[***] pricing for HMC Conforming Wafers and HMC Pre-Qual Production Wafers as
contemplated by Sections 5.1(c) and (d), then from [***] forward, the Parties
agree that a proportion of HMC DRAM Product for any particular Process Node
shall be included into the detailed calculation of the Price of Non-HMC
Conforming Wafers and Non-HMC Pre-Qual Production Wafers for such Process Node
stated in this Schedule 5.1; provided, however, such proportion of HMC DRAM
Product to be included shall be limited to [***].
Statement of Intent and Agreement:
The purpose of the above Section 5(e) is to memorialize the fundamental intent
and agreement of the Parties that when this Section 5(e) is applicable, the
calculation components of a proportion of HMC DRAM Product for any particular
Process Node shall be included in determining the Price of Non-HMC Conforming
Wafers and Non-HMC Pre-Qual Production Wafers for such Process Node. Apart from
when and how much HMC DRAM Product revenue to include in the Price

Schedule 5.1 – Page 12
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

calculation (about which the Parties hereby acknowledge they have reached
complete agreement and for which no further negotiation is necessary or
appropriate), the Parties also recognize that other portions of the Non-HMC
Conforming Wafers and Non-HMC Pre-Qual Production Wafers Price calculation (for
example, [***] and [***] ) cannot be finally concluded until the exact nature of
the HMC DRAM Products is known. Therefore, the Parties hereby agree that before
the time this Section 5(e) becomes applicable, they will negotiate in good faith
such portions of the Price formula not already definitely agreed. Given that
[***], the Parties hereby agree the negotiation referenced in the previous
sentence will be guided by and consistent with the pricing methodology already
agreed with respect to Multi-Chip Products.

Schedule 5.1 – Page 13
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

ATTACHMENT 1
TO SCHEDULE 5.1
EXAMPLE CALCULATIONS OF
NON-HMC CONFORMING WAFER PRICE
See attached.

Attachment 1 to Schedule 5.1 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Micron Technology, Inc. & Inotera Memories, Inc
Wafer Supply Agreement
Attachment 1 to Schedule 5.1
Example Calculation of Price of Non-HMC Conforming and Non-HMC Pre-Qual
Production Wafers

 
 
[***]
 
[***]
 
 
 
 
 
 
 
 
 
A
WW DRAM Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
C
Applicable DRAM Discount
 
[***]
 
 
 
[***]
 
 
 
A * (1 - C)
Discounted WW DRAM Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B1
Worldwide MCP Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***]
$
[***]
 
 
$
[***]
 
 
 
 
[***]
$
[***]
 
 
$
[***]
 
 
 
B2
[***] WW MCP Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B = B1-B2
[***] WW MCP Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
C
Applicable DRAM Discount
 
[***]
 
 
 
[***]
 
 
 
D
[***]
 
[***]
 
 
 
[***]
 
 
 
B * (1 - C - D)
Discounted [***] WW MCP Revenue per Node
$
[***]
 
 
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discounted WW Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
I
WW Revenue [***] Factor per Node
 
[***]
 
 
 
[***]
 
 
 
((A*(1-C))+(B*(1-C-D)))*(1+I)
Adj WW Revenue per Node
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G
WW [***] Wafer [***] per Node
 
[***]
 
 
 
[***]
 
 
 
E*F/G
Adjusted Revenue per Wafer
$
[***]
 
 
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
WW BE Cost per Node
$
[***]
 
 
$
[***]
 
 
 
F
[***]
 
[***]
 
 
 
[***]
 
 
 
E*F
Adjusted WW BE Cost per Node
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H
WW [***] Wafers to [***] per Node
 
[***]
 
 
 
[***]
 
 
 
E*F/H
Adjusted BEOL Costs per Wafer
 
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Price per Wafer
$
[***]
 
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***]
[***]
 
 
[***]
[***]
[***]
[***]
 
[***] per Wafer
$
[***]
[***]
 
$
[***]
[***]
[***]
[***]
 
 
 
 
 
 
 
 
 
 
 
 
Price
$
[***]
[***]
 
$
[***]
[***]
[***]
[***]

Attachment 1 to Schedule 5.1 – Page 2
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 1 to Schedule 5.1
Example Calculation of Worldwide Revenue [***] Factor per Node

 

 
 
[***]
 
[***]
 
 
 
 
 
J=A+B
WW Revenue per Node
$
[***]
 
$
[***]
G
WW [***] Wafer [***] per Node
 
[***]
 
 
[***]
 
 
 
 
 
 
 
 
WW Revenue per Wafer [***]
$
[***]
 
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K=[***]
[***] WW Revenue per Node
$
[***]
 
$
[***]
N=[***]
[***] WW  [***] Wafer [***] per Node
 
[***]
 
 
[***]
 
 
 
 
 
 
 
 
[***] WW Revenue per Wafer [***]
$
[***]
 
$
[***]
 
 
 
 
 
 
 
I=((J/G)-(K/N))/(K/N)
WW Revenue [***] Factor per Node
 
[***]
 
 
[***]

 

Attachment 1 to Schedule 5.1 – Page 3
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

Micron Technology, Inc. & Inotera Memories, Inc
First Amended and Restated Wafer Supply Agreement
Attachment 1 to Schedule 5.1
Example Calculation of [***] per Wafer
 
 
[***]
 
[***]
 
 
[***]
[***]
 
[***]
[***]
[***]
[***]
A
WW DRAM Revenue by DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
C
Applicable DRAM Discount
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
A* (1-C)
Discounted WW DRAM Revenue per DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B1
Worldwide MCP Revenue by DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***]
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
[***]
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
B2
[***] WW MCP Revneue by DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B-B1.B2
[***] WW MCP Revenue by DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
C
Applicable DRAM Discount
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
D
[***]
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
B*(1-C-D)
Discounted [***] WW MCP Revenue per Node
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WW Revenue Per Design ID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
M
WW Revenue [***] Factor per Node
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
((A*(1-C))+(B*(1-C-D)))*(1+M)
Adjusted WW Revenue per DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
WW BE Cost by DID
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
F
[***]
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
E*F
Adjusted Total BEOL Costs
$
[***]
%
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I
WW Die [***] per DID
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
J
WW Die [***] per DID
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K
[***] Average Prime Die per [***] Wafer
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
G
[***]
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***] per Wafer
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L
[***] Average Prime Die per [***] Wafer
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
H
[***]
 
[***]
 
[***]
 
 
[***]
 
[***]
 
[***]
 
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***] per Wafer
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[***] per Wafer
$
[***]
$
[***]
 
$
[***]
$
[***]
$
[***]
$
[***]

Attachment 1 to Schedule 5.1 – Page 4
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 5.2 – PRICE OF PRE-QUAL ENGINEERING WAFERS
The Parties agree that the price of each Pre-Qual Engineering Wafer of a
particular Design ID delivered in a particular Delivery Month shall be equal to
the quotient of (a) the [***] in such Delivery Month, divided by (b) the number
of Pre-Qual Engineering Wafers of such Design ID delivered by Inotera in such
Delivery Month. Notwithstanding anything to the contrary herein, the following
shall not be included in the calculation of the price for Pre-Qual Engineering
Wafers: (i) any [***]; (ii) any [***].

Schedule 5.2 – Page 1
DLI-266520155v1

--------------------------------------------------------------------------------

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

CONFIDENTIAL

SCHEDULE 12.15 - INSURANCE
1.    Property Insurance: All risk property insurance, including earth movement
and flood insurance, insuring against physical damage on a replacement cost
basis for assets, and insuring against resultant business interruption from
physical damage on an actual-loss sustained basis. Such property insurance limit
will be not less than [***] million for [***] and not less than [***] for other
covered losses. (Note: limits shared with NTC). It is acknowledged that: (1)
such coverage for “production related equipment” is based on Replacement Cost
Basis; and (2) non-production related assets (such as buildings, facilities, and
other non-production equipment) are insured under Actual Cash Value and such
coverage is subject to monthly adjustment depending on the actual cash value.
2.    Liability Insurance:
A.    Commercial general liability insurance (also known as public liability
insurance) coverage for bodily injury and property damage liability, with a
limit of not less than [***] for each loss occurrence and not less than [***]
million in annual aggregate coverage.
B.    Automobile liability coverage for bodily injury and property damage
liability with a limit of not less than [***] for each loss occurrence and not
less than [***] million in annual aggregate coverage for owned, hired, and
non-owned automobiles.
3.    Employers Liability: Employers’ liability coverage that is included in the
Labor Insurance Program or other equivalent program required under the
Applicable Laws of the R.O.C.

Schedule 12.15 – Page 1
DLI-266520155v1